<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006669" GROUP_ID="CHILDCA" ID="741806060616164869" MERGED_FROM="" MODIFIED="2010-11-09 13:40:14 +0100" MODIFIED_BY="Jos Noorman" NOTES="&lt;p&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 13:38:33 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="005" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2010-11-09 13:40:14 +0100" MODIFIED_BY="Jos Noorman">
<TITLE MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">High-dose chemotherapy for children and young adults with stage IV rhabdomyosarcoma</TITLE>
<CONTACT MODIFIED="2010-11-09 13:40:14 +0100" MODIFIED_BY="Jos Noorman"><PERSON ID="A9B10F6282E26AA201BA4B54A640DDAA" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Johannes</FIRST_NAME><MIDDLE_INITIALS>HM</MIDDLE_INITIALS><LAST_NAME>Merks</LAST_NAME><POSITION>Paediatric Oncologist</POSITION><EMAIL_1>j.h.merks@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Paediatric Oncology</DEPARTMENT><ORGANISATION>Emma Children's Hospital / Academic Medical Center</ORGANISATION><ADDRESS_1>PO Box 22660</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1100 DD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 5663050</PHONE_1><FAX_1>+31 20 6917735</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-11-09 13:40:14 +0100" MODIFIED_BY="Jos Noorman"><PERSON ID="DE84EEC182E26AA201BA4B541F8B9240" ROLE="AUTHOR"><FIRST_NAME>Rick</FIRST_NAME><LAST_NAME>Admiraal</LAST_NAME><POSITION>Student University of Amsterdam</POSITION><EMAIL_1>rick.admiraal@student.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Paediatrics</DEPARTMENT><ORGANISATION>Emma Children's Hospital / Academic Medical Center</ORGANISATION><ADDRESS_1>PO Box 22660</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1100 DD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 6 11210706</PHONE_1></ADDRESS></PERSON><PERSON ID="C5F5175E82E26AA201650CEAEBBF2290" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Marcel</FIRST_NAME><LAST_NAME>van der Paardt</LAST_NAME><ADDRESS><ORGANISATION>Academic Medical Center</ORGANISATION><ADDRESS_1>PO Box 22660</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1100 DD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON><PERSON ID="A9AFD78E82E26AA201BA4B54D31CB51C" ROLE="AUTHOR"><FIRST_NAME>Jasmijn</FIRST_NAME><LAST_NAME>Kobes</LAST_NAME><POSITION>CB doctor</POSITION><EMAIL_1>jasmijnkobes@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Child Health Care</DEPARTMENT><ORGANISATION>GGD Gooi &amp; Vechtstreek</ORGANISATION><ADDRESS_1>Heuvellaan 50</ADDRESS_1><CITY>Hilversum</CITY><ZIP>1217 JN</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 35 6926220</PHONE_1></ADDRESS></PERSON><PERSON ID="13704" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Leontien</FIRST_NAME><MIDDLE_INITIALS>CM</MIDDLE_INITIALS><LAST_NAME>Kremer</LAST_NAME><EMAIL_1>l.c.kremer@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Paediatric Oncology</DEPARTMENT><ORGANISATION>Emma Children's Hospital / Academic Medical Center</ORGANISATION><ADDRESS_1>PO Box 22660 (room G8-235)</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1100 DD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 5667132</PHONE_1><FAX_1>+31 20 5669690</FAX_1></ADDRESS></PERSON><PERSON ID="608407CA82E26AA2011EF9F6BB73141B" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Gianni</FIRST_NAME><LAST_NAME>Bisogno</LAST_NAME><POSITION>Pediatric Oncologist</POSITION><EMAIL_1>gianni.bisogno@unipd.it</EMAIL_1><ADDRESS><DEPARTMENT>Paediatrics</DEPARTMENT><ORGANISATION>University Hospital of Padova</ORGANISATION><ADDRESS_1>Via Giustiniani 3</ADDRESS_1><CITY>Padova</CITY><ZIP>35128</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 0498211481</PHONE_1><PHONE_2>+39 049-8211462</PHONE_2></ADDRESS></PERSON><PERSON ID="A9B10F6282E26AA201BA4B54A640DDAA" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Johannes</FIRST_NAME><MIDDLE_INITIALS>HM</MIDDLE_INITIALS><LAST_NAME>Merks</LAST_NAME><POSITION>Paediatric Oncologist</POSITION><EMAIL_1>j.h.merks@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Paediatric Oncology</DEPARTMENT><ORGANISATION>Emma Children's Hospital / Academic Medical Center</ORGANISATION><ADDRESS_1>PO Box 22660</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1100 DD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 5663050</PHONE_1><FAX_1>+31 20 6917735</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-11-09 13:38:33 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="22" MONTH="9" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="23" MONTH="3" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="8" MONTH="9" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2010-09-20 11:11:33 +0200" MODIFIED_BY="[Empty name]"/>
<HISTORY MODIFIED="2010-09-20 11:11:33 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-09-20 11:11:33 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-09-20 12:35:07 +0200" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2009-09-21 13:08:09 +0200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-09-21 13:03:17 +0200" MODIFIED_BY="[Empty name]">
<NAME>Dutch Cochrane Center</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2010-09-20 12:35:07 +0200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-09-20 12:35:07 +0200" MODIFIED_BY="[Empty name]">
<NAME>No source of support</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-11-09 11:05:50 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">High-dose chemotherapy for children and young adults with metastatic rhabdomyosarcoma</TITLE>
<SUMMARY_BODY MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<P>Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood. Fifteen percent of  rhabdomyosarcoma patients already have metastases when the disease is discovered. With conventional dose chemotherapy survival generally is poor, therefore using 'high-dose' chemotherapy has been studied to see if this can improve survival. This type of chemotherapy has been shown to improve survival in metastatic neuroblastoma, another type of childhood cancer, when given after conventional chemotherapy with only very small amounts of neuroblastoma left. This might also be true for metastatic rhabdomyosarcoma. An alternative way of using high-dose chemotherapy is to use it 'up front', at the start of treatment; applied this way it could potentially kill tumour cells before resistance to chemotherapy develops.</P>
<P>Besides creating a possible benefit for patients, high-dose chemotherapy introduces significant extra risk of side effects above those of conventional chemotherapy. These include mucositis (severe inflammation of the mouth and gut) and bone marrow aplasia (when the body cannot make any blood elements and is at risk of life-threatening bleeding and infection). The administration of cells which can restore the bone marrow (haemopoietic stem cells) reduces this risk. These stem cells come from the patient themselves (autologous) or are donated from volunteers (allogenic). During the first weeks after high-dose chemotherapy, infections, bleeding and metabolic problems may occur, possibly counteracting the potential benefit of improved tumour control. In this review the authors analysed all relevant studies on the use of high-dose chemotherapy in metastatic rhabdomyosarcoma patients. The authors of this review found no evidence that supported the use of high-dose chemotherapy as a standard therapy for metastatic rhabdomyosarcoma.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<P>Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood. Prognosis for patients with metastatic disease has not improved significantly in the past decades. High-dose chemotherapy (HDC) seems to be an attractive option to treat minimal residual disease in metastatic rhabdomyosarcoma patients.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<P>The objective of the review was to assess the effectiveness of HDC with stem cell rescue (SRC) versus standard-dose chemotherapy in improving event-free survival (EFS) and overall survival (OS) of children and young adults with metastatic rhabdomyosarcoma.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the databases of MEDLINE (1966 to December 2009), EMBASE (1980 to December 2009) and CENTRAL (<I>The Cochrane Library</I> Issue 1, 2009). In addition, we handsearched the reference lists of selected papers and conference proceedings of the SIOP, ASPHO and ASCO meetings (all 2000 to 2009).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCT), prospective or historical controlled clinical trials (CCT), in which HDC with SCR was compared to conventional chemotherapy and prospective case series (non-controlled clinical trials) including at least 20 naive metastatic rhabdomyosarcoma patients</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently performed the study selection, quality assessment and data extraction.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<P>No RCTs could be identified. We identified one prospective CCT, one retrospective CCT and one non-controlled clinical trial. Another CCT has been published as an abstract. All studies have severe methodological limitations, in particular selection bias could not be excluded. One CCT reported a significantly worse OS compared to oral maintenance therapy, however in a subgroup of high-risk patients no difference could be found. The retrospective CCT reported a similar survival for HDC compared to conventional chemotherapy. The non-controlled clinical trial and the CCT reported as a conference proceeding reported survival outcomes comparable to previous studies. Data on toxicity showed more grade 3-4 toxicity in the HDC group. However, there was no difference in the number of toxic deaths.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<P>Overall, the results of this review do not justify the use of HDC with SCR as a standard therapy for children with metastatic rhabdomyosarcoma. However, all reported studies were possibly subject to significant bias, especially selection bias. This might have underestimated the measured effect of HDC. As a result, a clinically important excess of adverse risk patients in the HDC arms may explain the non-beneficial effect of HDC. Only a large prospective RCT will be able to answer the question of whether HDC with SCR adds to survival or not definitively.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-11-09 11:05:50 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<P>Rhabdomyosarcoma (RMS) is the most common malignant soft-tissue sarcoma of childhood, accounting for approximately 6% of paediatric tumours (<LINK REF="REF-Carli-2004" TYPE="REFERENCE">Carli 2004</LINK>), with an age-standardised annual incidence rate of four to seven per million (<LINK REF="REF-Stiller-1994" TYPE="REFERENCE">Stiller 1994</LINK>; <LINK REF="REF-Grovas-1997" TYPE="REFERENCE">Grovas 1997</LINK>). Most children with RMS present with localised disease. With the introduction of multimodal therapy the prognosis of patients with localised disease has improved steadily over the last three decades, with a cure rate of approximately 70% to 80% (<LINK REF="STD-Koscielniak-1997" TYPE="STUDY">Koscielniak 1997</LINK>; <LINK REF="REF-Crist-2001" TYPE="REFERENCE">Crist 2001</LINK>, <LINK REF="REF-Stevens-2005" TYPE="REFERENCE">Stevens 2005</LINK>).</P>
<P>However, for the approximately 15% of children with RMS who present with metastatic disease (stage IV RMS), prognosis has not improved significantly despite the introduction of new drugs and the intensification of treatment. The overall survival remains at approximately 20% to 30% in this group (<LINK REF="REF-Breneman-2003" TYPE="REFERENCE">Breneman 2003</LINK>; <LINK REF="REF-Carli-2004" TYPE="REFERENCE">Carli 2004</LINK>).<BR/>Multivariable analyses of the most recent European and North American stage IV RMS trials showed four factors that independently and significantly correlated with improved survival: favourable tumour sites (genitourinary, head and neck); absence of bone or bone marrow metastases; age between one and nine years; and two or fewer metastatic sites (<LINK REF="REF-Oberlin-2008" TYPE="REFERENCE">Oberlin 2008</LINK>).</P>
<P>High-dose chemotherapy (HDC) with autologous stem cell rescue (SCR), using either the patient's bone marrow (BM) or peripheral blood stem cells (PBSC), is one of the second-line therapy options in various unfavourable patient categories with diverse paediatric solid tumours (<LINK REF="REF-Fraser-2006" TYPE="REFERENCE">Fraser 2006</LINK>; <LINK REF="REF-Lee-2008" TYPE="REFERENCE">Lee 2008</LINK>; <LINK REF="REF-Rosenthal-2008" TYPE="REFERENCE">Rosenthal 2008</LINK>; <LINK REF="REF-Spreafico-2008" TYPE="REFERENCE">Spreafico 2008</LINK>). The hypothesis is that myeloablative conditioning regimens may overcome resistance to standard polychemotherapy. Their use has been established as standard care for children with unfavourable disease in neuroblastoma only (<LINK REF="REF-Matthay-1999" TYPE="REFERENCE">Matthay 1999</LINK>); the benefits of HDC apparently outweigh the risks of the treatment in this patient group. Experience with HDC and allogenic SCR has so far only been piloted in few patients with solid tumours, and its value remains to be proven.</P>
<P>To improve the outcome of stage IV RMS, various studies have used HDC with autologous SCR for children in complete remission after standard therapy in order to treat minimal residual disease (<LINK REF="REF-Hartmann-1991" TYPE="REFERENCE">Hartmann 1991</LINK>; <LINK REF="REF-Pinkerton-1991" TYPE="REFERENCE">Pinkerton 1991</LINK>; <LINK REF="REF-Dumontet-1992" TYPE="REFERENCE">Dumontet 1992</LINK>; <LINK REF="STD-Foot-1997" TYPE="STUDY">Foot 1997</LINK>; <LINK REF="STD-Koscielniak-1997" TYPE="STUDY">Koscielniak 1997</LINK>; <LINK REF="STD-Boulad-1998" TYPE="STUDY">Boulad 1998</LINK>; <LINK REF="STD-Carli-1999" TYPE="STUDY">Carli 1999</LINK>; <LINK REF="STD-McDowell-2005" TYPE="STUDY">McDowell 2005</LINK>; <LINK REF="STD-Klingebiel-2008" TYPE="STUDY">Klingebiel 2008</LINK>; <LINK REF="STD-Bisogno-2009" TYPE="STUDY">Bisogno 2009</LINK>). However, its value in RMS stage IV remains unclear. No prior systematic review on the efficacy of high-dose chemotherapy in RMS stage IV has been carried out.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Primary objective</HEADING>
<P>To assess the effectiveness of high-dose chemotherapy with autologous stem cell rescue or allogenic stem cell rescue (versus standard-dose chemotherapy) in improving event-free survival (EFS) and overall survival (OS) of children and young adults with stage IV rhabdomyosarcoma.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Secondary objective</HEADING>
<P>To determine the toxicity of high-dose chemotherapy.</P>
</SUBSECTION>
</OBJECTIVES>
<METHODS MODIFIED="2010-11-04 23:09:15 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) or (historical) controlled clinical trials (CCTs) that compare the effectiveness of high-dose chemotherapy and autologous stem cell rescue or allogenic stem cell rescue with standard dose chemotherapy for children with stage IV rhabdomyosarcoma. Prospective non-controlled clinical trials (prospective patient series) describing more than 20 cases were also included; the number of more than 20 cases was arbitrarily chosen.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-09-04 12:52:51 +0200" MODIFIED_BY="[Empty name]">
<P>Children and young adults (aged 0 to 29 years) with a diagnosis of RMS confirmed by pathology and evidence of distant metastases. Patients were considered to have distant metastases when the tumour was detected clinically or radiographically at one or more sites distant from the primary site and outside the regional lymph nodes.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>High-dose chemotherapy with autologous stem cell rescue or allogenic stem cell rescue versus conventional standard-dose chemotherapy. High-dose chemotherapy was defined as chemotherapy that ablates the patient&#8217;s bone marrow reserves and creates an absolute requirement for stem cell rescue. Standard-dose chemotherapy was defined as chemotherapy at a lower dose than high-dose chemotherapy that does not require stem cell rescue.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<UL>
<LI>EFS (defined as the interval between diagnosis and date of first progression, relapse or death from any cause).</LI>
<LI>OS (defined as the time interval between diagnosis and the date of last follow up or death).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome</HEADING>
<UL>
<LI>Toxicity registered according to common toxicity criteria (CTC).</LI>
<LI>Quality of life</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-11-04 23:09:15 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the following electronic databases: MEDLINE/PubMed (from 1966 to December 2009), EMBASE/Ovid (from 1980 to December 2009) and CENTRAL (<I>The Cochrane Library</I> Issue 1, 2009). We used the subject headings and text words shown in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>, <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> and <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>. The search filter for children was developed by the Cochrane Childhood Cancer Group.</P>
<P>We located information about trials not registered in MEDLINE, EMBASE or CENTRAL, either published or unpublished, by searching the reference lists of relevant articles and review articles. We also scanned the conference proceedings of the International Society for Paediatric Oncology (SIOP), American Society for Pediatric Hematology and Oncology (ASPHO) and the American Society for Clinical Oncology (ASCO), from 2000 to 2009; electronically if available and otherwise by handsearching. We researched ongoing trials by contacting researchers involved in this area and also by scanning the ISRCTN registry and the National Institute of Health Registry, (<A HREF="http://www.controlled-trials.com">http://www.controlled-trials.com</A>). We did not impose language restrictions.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Selection of the studies</HEADING>
<P>After employing the search strategy described previously, two review authors (RA, MvdP) undertook identification of studies meeting the inclusion criteria independently. Discrepancies were resolved by discussion. If consensus could not be reached, a final resolution was made by a paediatric oncologist (JHMM). We obtained any study seemingly meeting the inclusion criteria on grounds of title, abstract or both in full for closer inspection. Details of reasons for exclusion of any study considered for review are clearly stated.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of risk of bias in included studies</HEADING>
<P>We assessed the risk of bias according the guidelines of the <I>Cochrane Handbook for Systematic Review of Interventions </I>(<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). Since there were no randomised controlled trials included, and different aspects of the quality of the studies should be reported, we had to adjust the quality assessment criteria. Furthermore, we assessed the quality of reporting of the study and control group, interventions, follow up and outcome. Two independent review authors (RA, MvdP) assessed risk of bias and quality of reporting. If consensus could not be reached, a final resolution was made by a paediatric oncologist (JHMM). We assessed the quality of reporting and the risk of bias (i.e. risk of selection bias, performance bias, attrition bias, detection bias) using various items (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>Two review authors (RA, MvdP) performed data extraction independently using standardised forms. We extracted data on the characteristics of the participants (age, sex, histology, size and site of primary tumour, metastatic site(s), node stage, received induction treatment, received local therapy, remission status at time of high-dose therapy and stem cell rescue); of interventions (details for high-dose chemotherapy on drugs used, routes of delivery, dose, timing, use of total body irradiation; details for the stem cell rescue on timing and methods of stem cell harvest, timing of transplantation, number of cells infused, possible contamination with tumour cells); of supportive care (like the use of growth factors); of outcome measures, and of length of follow up. In case of disagreement, we re-examined and discussed the abstracts and articles until consensus was achieved. If consensus could not be reached then final resolution was made by a paediatric oncologist (JHMM).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>As no randomised controlled trials were included, and statistical pooling of data was not possible due to the heterogeneity of the study designs, study groups and treatment, we only present descriptive data from the individual studies. In the individual studies the log-rank test was used to compare survival rates, if applicable (<LINK REF="STD-Klingebiel-2008" TYPE="STUDY">Klingebiel 2008</LINK>; <LINK REF="STD-Carli-1999" TYPE="STUDY">Carli 1999</LINK>).</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-11-04 23:25:17 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-11-04 23:25:17 +0100" MODIFIED_BY="[Empty name]">
<P>The search strategy retrieved 3120 records from MEDLINE, 325 from EMBASE and 31 from CENTRAL (total 3476). Based on title and abstract we submitted a total of 44 studies for further reading of the full-text article. Of these articles, one historical controlled clinical trial, one prospective controlled clinical trial and one non-controlled clinical trial were included (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). We excluded a total of 41 studies for a variety of reasons (<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> and <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). We excluded the remaining 3432 articles since they did not include at least 20 patients with stage IV rhabdomyosarcoma, were not treated with high-dose chemotherapy, were retrospective case series or were reviews.</P>
<P>From scanning the reference lists of the 44 full-text articles, we identified five additional studies. However, they did not fulfil all criteria for considering studies for this review and were thus added to the table of excluded studies (<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
<P>From scanning the conference proceedings of SIOP, ASPHO and ASCO we identified two additional studies. One fulfilled the criteria for considering studies for this review; this conference proceeding included a prospective controlled clinical trial (<LINK REF="STD-McDowell-2005" TYPE="STUDY">McDowell 2005</LINK>). We excluded a second abstract since it did not include at least 20 patients with stage IV rhabdomyosarcoma (<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
<P>From scanning the International Standard Randomised Controlled Trial Number (ISRCTN) register and the National Health Institute (NIH) register we identified no additional studies.</P>
<P>Therefore, the total number of included studies was three (<LINK REF="STD-Carli-1999" TYPE="STUDY">Carli 1999</LINK>; <LINK REF="STD-Klingebiel-2008" TYPE="STUDY">Klingebiel 2008</LINK>; <LINK REF="STD-Bisogno-2009" TYPE="STUDY">Bisogno 2009</LINK>) (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). Additionally we identified one study, published as an abstract (<LINK REF="STD-McDowell-2005" TYPE="STUDY">McDowell 2005</LINK>) (<LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>).</P>
<P>Three different strategies of high-dose chemotherapy were used. <LINK REF="STD-Klingebiel-2008" TYPE="STUDY">Klingebiel 2008</LINK> and <LINK REF="STD-Carli-1999" TYPE="STUDY">Carli 1999</LINK> used high-dose chemotherapy as consolidation treatment in children achieving complete remission after standard chemo- and local therapy. <LINK REF="STD-Bisogno-2009" TYPE="STUDY">Bisogno 2009</LINK> applied HDC earlier in the treatment, i.e. after three initial courses (= one cycle) of conventional chemotherapy but before local therapy. In the trial reported only in an abstract (<LINK REF="STD-McDowell-2005" TYPE="STUDY">McDowell 2005</LINK>), high-dose chemotherapy was used up front. In both latter trials HDC was used more up front with the aim of avoiding the occurrence of drug resistance.</P>
<SUBSECTION>
<HEADING LEVEL="3">Included studies</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Randomised controlled trials</HEADING>
<P>No RCTs were identified which investigated the effectiveness of high-dose chemotherapy with autologous stem cell rescue or allogenic stem cell rescue versus standard-dose chemotherapy in improving event-free survival (EFS) and/or overall survival (OS) of children with stage IV rhabdomyosarcoma.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Controlled clinical trial</HEADING>
<P>
<LINK REF="STD-Klingebiel-2008" TYPE="STUDY">Klingebiel 2008</LINK> performed a prospective controlled clinical trial. This CCT investigated the effectiveness of high-dose chemotherapy with autologous stem cell rescue or allogenic stem cell rescue versus standard-dose chemotherapy in improving event-free survival (EFS) and overall survival (OS) of children with stage IV rhabdomyosarcoma.</P>
<P>In the international multicentre study HD CWS-96, 295 soft tissue sarcoma (STS) patients were registered between May 1995 and December 2003; all patients fulfilled the study eligibility criteria (Stage IV STS, &lt; 22 years old, no previous malignancy or treatment apart from surgery). Insufficient treatment data were available in 37 patients. Of the remaining 258 patients, 162 patients did not receive the scheduled treatment and were excluded from analysis. Ninety-six patients (74 with RMS) completed either the high-dose chemotherapy arm (HDC; n = 45; 34 RMS) or oral treatment arm (OT; n = 51; 40 RMS). Allocation of treatment was based on the responsible physician&#8217;s decision.</P>
<P>Both groups were pre-treated with CEVAIE (carboplatin, epirubicin, vincristine, actinomycin D, ifosfamide and etoposide). The HDC patients received seven CEVAIE courses, OT patients received 9 CEVAIE courses (= three cycles). HDC consisted of a tandem cycle of thiotepa (600 mg/m²) and cyclophosphamide (4500 mg/m²), followed by melphalan (120 mg/m²) and etoposide (1800 mg/m²), followed by autologous stem cell rescue. The OT group received four cycles (22 weeks) of oral therapy, consisting of the combination of trofosfamide and etoposide alternating with trofosfamide and idarubicin. The HDC group had a slight overrepresentation of high-risk factors, as identified by <LINK REF="REF-Oberlin-2008" TYPE="REFERENCE">Oberlin 2008</LINK>; age &lt; 1 or &gt; 10 years was reported in 61% versus 54.9% of cases (P = 0.48), unfavourable sites were present in 71% versus 67%, and bone/bone marrow involvement occurred in 53% versus 37% (P = 0.10), respectively. However, no significant differences in risk factors were found. Although the number of non-RMS soft tissue sarcoma cases in this series was low, patient characteristics were not separately reported for RMS and non-RMS cases. Local therapy was planned after the third CEVAIE cycle; details on actual local therapy received were not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Historical controlled clinical trial</HEADING>
<P>One historical controlled trial (<LINK REF="STD-Carli-1999" TYPE="STUDY">Carli 1999</LINK>) was identified which investigated the effectiveness of high-dose chemotherapy with autologous stem cell rescue or allogenic stem cell rescue versus standard dose chemotherapy in improving event-free survival (EFS) and overall survival (OS) of children with stage IV rhabdomyosarcoma.</P>
<P>The prospective historical controlled clinical trial (<LINK REF="STD-Carli-1999" TYPE="STUDY">Carli 1999</LINK>) included 96 children with metastatic rhabdomyosarcoma in clinical complete remission (CR) before the third cycle of intensive multi-agent chemotherapy out of an original cohort of 174 children with stage IV RMS. Patients varied in age from three months to 18 years. It was a European multicentre study, and allocation of treatment was based on time of diagnosis and centre-based choice to treat all patients either with high-dose chemotherapy (HDC) or standard therapy (ST). The high-dose chemotherapy group (52 children) consisted of patients who presented from 1991 until 1995 in centres capable of giving high-dose chemotherapy according to the MMT4-91 protocol. The standard therapy group (44 children) either presented from 1989 until 1991, a period where all centres treated all stage IV patients according to protocol MMT4-89 or from 1991 until 1995 in a centre not capable of giving high-dose chemotherapy. All patients were pre-treated with three cycles (consisting of three courses each) of intensive multi-agent chemotherapy consisting of epirubicin, carboplatin, vincristine, ifosfamide, actinomycin and etoposide. The HDC group received high-dose melphalan (200 mg/m²) (42 children) or another combination of agents (10 children). Used combinations were melphalan, carboplatin and etoposide (two children), melphalan and etoposide (two children), thiotepa, busulfan and etoposide (two children), epidoxorubicin and etoposide (two children), carboplatin and etoposide (one child) and thiotepa, busulfan and melphalan (one child). The ST group received a last cycle identical to the first three cycles of intensive multi agent chemotherapy. Patients treated with HDC received autologous bone marrow or peripheral blood stem cell transplantation, harvested after the third cycle in children who had bone marrow metastases at diagnosis or after the second cycle in those who had not. In the HDC group, 67.7% had surgery versus 51.7% in the ST group (P = 0.5). Radiotherapy was given in 43.8% of HDC patients versus 53.3% of ST patients (P = 0.7). Patients with age &lt; 1 or &gt; 10 years were equally present in the ST and HDC group (39% versus 40%). The same applies for distribution of unfavourable sites (presence in ST versus HDC group 76% versus 78%; P = 0.6), although parameningeal sites were included together with extremities and other sites here. Standard therapy patients were slightly more likely to have unfavourable metastatic sites than the HDC group (79.5% versus 75%). Comparing individual metastatic sites, percentages for the ST group versus the HDC group were: lung 43% versus 44% (P = 0.9)), bone 30% versus 25% (P = 0.62), bone marrow 36% versus 23% (P = 0.15). Lymph node metastases occurred significantly more often in the HDC group versus the ST group (56% versus 39%; P = 0.03).  </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Prospective non-controlled clinical trial (single-arm trial)</HEADING>
<P>One prospective, non-controlled clinical trial (<LINK REF="STD-Bisogno-2009" TYPE="STUDY">Bisogno 2009</LINK>) was identified which investigated the effectiveness of high-dose chemotherapy with autologous stem cell rescue in improving event-free survival (EFS) and overall survival (OS) of children with stage IV rhabdomyosarcoma.</P>
<P>
<LINK REF="STD-Bisogno-2009" TYPE="STUDY">Bisogno 2009</LINK> described a prospective non-controlled clinical trial. From 1999 to 2006, 70 patients were registered in this Italian national multicentre study (RMS4.99). Age ranged from 0.9 months to 20.9 years with a median age of 9.4 years. All patients received induction chemotherapy consisting of one cycle (consisting of three courses) of CEVAIE (carboplatin, epirubicin, vincristine, actinomycin, ifosfamide and etoposide) in 30 patients (1999 to May 2002) and IVADo (ifosfamide, vincristine, actinomycin and doxorubicin) in 40 patients (June 2002 to 2006). Patients who responded to induction chemotherapy (tumour reduction of more than 25%) and showed disappearance (or persistent absence) of bone marrow infiltration received HDC. Cyclophosphamide 2 gr/m<SUP>2</SUP> and etoposide 200 mg/m<SUP>2 </SUP>were administered to obtain a minimum of 8 x 10<SUP>6</SUP>/kg CD34 peripheral blood stem cells. Thereafter three consecutive high-dose combinations with G-CSF support and SCT were administered; a first course of thiotepa (150 mg/m<SUP>2</SUP> x 2) and melphalan (60 mg/m<SUP>2</SUP>), a second course of cyclophosphamide (2 gr/m<SUP>2</SUP>) and thiotepa (150 mg/m<SUP>2 </SUP>x 2) and a third course of melphalan (80 mg/m<SUP>2</SUP>). HDC was administered to 62 patients, but was not completed in five patients because of toxicity (three) or tumour progression (two). HDC was not given in eight children because of progressive disease during induction chemotherapy (four), very poor general condition (three) or persistence of bone marrow disease (one). The primary tumour was resected after HDC in 13 patients, surgery being complete in seven. Forty-five patients received radiotherapy. After the HDC phase, 41 patients continued with six courses of VAC (combination of vincristine, actinomycin D and cyclophosphamide). Unfavourable age of &lt; 1 or &gt; 10 was present in 33 (47%), 26 (37%) had limbs or 'other' as primary site, 22 (31%) had bone marrow, 27 (39%) had bone metastases, and 18 (26%) had more than two metastatic sites.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Unpublished studies awaiting assessment (abstract only)</HEADING>
<P>
<LINK REF="STD-McDowell-2005" TYPE="STUDY">McDowell 2005</LINK> performed a prospective controlled clinical trial. The MMT-98 study was a European multicentre study and included patients with metastatic RMS who presented from 1998 until 2004. Out of an original cohort of 112 children, 74 children were considered high-risk (HR: age &gt;= 10 years or bone or bone marrow involvement). Participating centres had to make a choice to treat HR-patients with either high-dose chemotherapy (HDC) or with standard therapy (ST). Of these 74 HR patients, 46 received HDC and 28 ST. HDC consisted of a first phase of two courses of a phase II window study (either carboplatin or doxorubicin) followed by a second phase of sequential high-dose monotherapy (SHDMT). SHDMT consisted of sequential high doses of cyclophosphamide, etoposide, cyclophosphamide and carboplatin, followed by an autologous stem cell transplantation, intensive local treatment and VAC maintenance (combination of vincristine, actinomycin D and cyclophosphamide for nine courses). ST patients received nine courses (= three cycles) of intensive six drug chemotherapy (epirubicin, carboplatin, vincristine, ifosfamide, actinomycin and etoposide) followed by the same VAC maintenance. Intensive local treatment was planned after the sixth course of intensive chemotherapy.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Included studies</HEADING>
<P>We assessed the risk of bias according an adjustment of the quality assessment reported in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>) (<LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK>; <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) The results of the quality of reporting are presented in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> (External validity study/control group, intervention, follow up and outcome).</P>
<P>None of the studies was a RCT. In the prospective CCT the selection was based on physician&#8217;s decision (<LINK REF="STD-Klingebiel-2008" TYPE="STUDY">Klingebiel 2008</LINK>), and in the historical CCT a centre-based selection was used (<LINK REF="STD-Carli-1999" TYPE="STUDY">Carli 1999</LINK>). One study did not include a control group in the trial (<LINK REF="STD-Bisogno-2009" TYPE="STUDY">Bisogno 2009</LINK>). The non-randomised selection of the study and control group could have introduced important selection bias. With regard to the centre-based selection, specialised paediatric oncology centres able to perform high-dose chemotherapy might attract higher risk patients; this selection could negatively influence EFS and OS in the HDC group. When treatment allocation is based on physician&#8217;s decision, low-risk patients might be more likely to be allocated to the less intensive treatment arm, as one is less inclined to accept the treatment related risks associated with high-dose chemotherapy. This also could have negatively influenced EFS and OS in the HDC group.</P>
<P>Both controlled clinical trials were not blinded to the intervention; this could have introduced performance bias. Although there was no blind outcome assessment, the risk of detection bias is low because the outcomes (EFS and OS) are objective outcome measurements.</P>
<P>The risk of attrition bias is low in the study of <LINK REF="STD-Carli-1999" TYPE="STUDY">Carli 1999</LINK> (<LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK>). However, in the other study from <LINK REF="STD-Klingebiel-2008" TYPE="STUDY">Klingebiel 2008</LINK> attrition bias could not be excluded. In this study the outcome was not assessed in all patients and not all patients were included in the analyses.</P>
<P>The external validity was acceptable in both controlled clinical trials (<LINK REF="STD-Carli-1999" TYPE="STUDY">Carli 1999</LINK>; <LINK REF="STD-Klingebiel-2008" TYPE="STUDY">Klingebiel 2008</LINK>) and in the single arm study (<LINK REF="STD-Bisogno-2009" TYPE="STUDY">Bisogno 2009</LINK>) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>One conference proceeding (<LINK REF="STD-McDowell-2005" TYPE="STUDY">McDowell 2005</LINK>) is a brief report presenting preliminary study results of a controlled clinical study with a centre-based selection of groups. Risk of bias could not be evaluated because of scarce data available. The full paper is expected to be published in the near future.</P>
<P>Furthermore publication bias can not be excluded. For example, the study of <LINK REF="STD-McDowell-2005" TYPE="STUDY">McDowell 2005</LINK> with negative results has not been published yet.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>All studies reported overall survival (OS), all but <LINK REF="STD-Klingebiel-2008" TYPE="STUDY">Klingebiel 2008</LINK> reported event-free survival (EFS) and all studies reported adverse effects. None of the studies reported quality of life.</P>
<SUBSECTION>
<HEADING LEVEL="3">Included studies</HEADING>
<P>The results of the EFS and OS of the three included studies are presented in<B> </B>
<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.</P>
<P>
<LINK REF="STD-Klingebiel-2008" TYPE="STUDY">Klingebiel 2008</LINK> defined EFS as the time between first diagnosis and death, progression or local and/or metastatic relapse. OS was defined as the period between first diagnosis and death. The toxicity was graded and registered according to WHO. Median follow up was 57.4 months.</P>
<P>EFS was not reported for the HDC and OT group separately. Five-year OS was reported for RMS patients in the HDC group (n = 34) and OT group (n = 40) separately, being respectively 15% (95% CI 3% to 27%) versus 52% (95% CI 34% to 68%) (P &lt; 0.001). When in the total cohort (n = 96) only patients without bone or bone marrow disease were considered, OS remained significantly worse for the HDC group (n = 20) versus the OT group (n = 31), OS reported being 40% (95% CI 19% to 61%) and 73% (95% CI 57% to 89%) respectively (P = 0.04).  For high-risk patients with bone marrow and/or bone involvement the difference was not statistically significant; for the HDC group (n = 24) five-year OS was 13% (CI 1% to 25%), for the OT group (n = 19) 17% (CI 1% to 33%). Acute toxicity was reported for 87/96 patients. Grade 3-4 toxicity according to WHO occurred more often in the HDC (n = 39) compared to the OT group (n = 48); grade 3-4 toxicity for Karnofsky index occurred in five HDC versus two OT patients, grade 3-4 infections in 10 versus three, platelet toxicity in 22 versus nine and gastrointestinal toxicity in 13 HDC versus two OT patients. Other acute toxicities (i.e. skin, liver, cardiac, pulmonary, kidney, peripheral and central neurotoxicity) did not show important differences. One patient died in the HDC group of chemotherapy-related toxicity (not specified). Twenty-two late effects were reported for 51 OT patients, while 18 late effects were documented for 45 HCT patients; late effects compromising kidney function occurred in 7/51 OT patients versus 1/45 HDC patients; late effects for other organ systems (i.e. neuropathy, cardiomyopathy and hepatosis) did not differ.</P>
<P>
<LINK REF="STD-Carli-1999" TYPE="STUDY">Carli 1999</LINK> defined EFS as the time from the interval between diagnosis and the date of first progression, relapse or death from any cause. OS was defined as the period between the date of diagnosis and the date of last follow up or death. Toxicity was registered according to the Common Toxicity Criteria. The median follow up was eight years.</P>
<P>The five-year EFS in the HDC group was 29% (95% CI 16% to 41%), EFS in the ST group was 23% (95% CI 11% to 36%). The five-year OS was 36% (95% CI 23% to 49%) in the HDC group versus 27% (95% CI 14% to 41%) in the ST group. The toxicity in the HDC group was comparable to previously reported data in other tumour types; the median time for neutrophil recovery (&gt; 500/&#956;L) was 16 days; median time for platelet recovery (&gt; 50,000/&#956;L) was 41 days. One toxic death occurred in the HDC group in the form of sepsis compared to one toxic death in the ST group because of cardiac toxicity.</P>
<P>
<LINK REF="STD-Bisogno-2009" TYPE="STUDY">Bisogno 2009</LINK> defined EFS as the period from diagnosis to first progression, relapse, death from any cause or latest contact for children who never experienced an event. OS was defined as the period from diagnosis to latest follow up or death from any cause. Toxicity was registered according to the Common Toxicity Criteria v2.0. Median follow up was five years (2.5 to 9.6).</P>
<P>The three-year EFS was 35.3%; three-year OS was 42.3%. Three patients died of treatment-related causes; two of septic shock and one of capillary leak syndrome after abdominal radiotherapy. Overall, more grade IV toxicity was reported while on IVADo when compared to CEVAIE. Severe infections were reported in the HDC phase, with two children developing fungal infections, one an interstitial pneumonia. Two of these three patients could not continue their HDC phase. Grade IV myelotoxicity was common throughout treatment; this caused one patient to stop HDC; two patients could not complete maintenance chemotherapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Unpublished studies awaiting assessment</HEADING>
<P>
<LINK REF="STD-McDowell-2005" TYPE="STUDY">McDowell 2005</LINK> did not give a definition for EFS, OS and toxicities. Median follow up was 11.4 months. The two-year EFS in the HDC group was 12%; EFS in the ST group was 42.1%. The two-year OS was 30.3% for the HDC group versus 51% for the ST group. No toxicities were reported. Confidence intervals and P values were not given.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-11-09 11:05:50 +0100" MODIFIED_BY="[Empty name]">
<P>The systematic review of the literature does not support the use of high-dose chemotherapy and stem cell transplantation in the treatment of naive stage IV rhabdomyosarcoma patients. However, none of the reported studies were randomised. As a result both controlled clinical trials (CCTs) have a high risk of selection bias. This could have influenced the results of these studies.</P>
<P>The prospective CCT of <LINK REF="STD-Klingebiel-2008" TYPE="STUDY">Klingebiel 2008</LINK> compared high-dose chemotherapy (HDC) with oral treatment (OT) in a CCT, both applied after standard multidrug chemotherapy and local treatment. Allocation of treatment was based on the physician&#8217;s choice. This might have underestimated the beneficial effect of high-dose chemotherapy, as centres able to perform this more complicated treatment are often referral centres for the more difficult, high-risk patients. They reported a significant decrease in overall survival (OS) for patients in the HDC group compared to the OT group; the two patient groups did not differ significantly for high-risk features. However, when only high risk patients with bone or bone marrow involvement were compared, survival figures were similar. Comparison of survival between HDC and OT patients specified for subgroups with other high-risk characteristics (i.e. age &lt; 1 or &gt; 10 years, unfavourable site, &gt; 2 metastatic sites) were not reported.</P>
<P>In the historical CCT of <LINK REF="STD-Carli-1999" TYPE="STUDY">Carli 1999</LINK>, a relatively small number of patients was included and treatment allocation was in part centre-based. Survival figures showed some suggestion for better survival in children treated with high-dose chemotherapy compared to standard therapy but there was no statistical significant difference. However, as part of the treatment allocation was centre-based, this again might have underestimated the beneficial effect of high-dose chemotherapy, as centres able to perform this more complicated treatment are often referral centres for the more difficult, high-risk patients. However, when the two patient groups were compared for high-risk features, no statistical differences were found.</P>
<P>
<LINK REF="STD-Bisogno-2009" TYPE="STUDY">Bisogno 2009</LINK> reported a non-controlled clinical trial in which high-dose chemotherapy was given early after three courses of induction chemotherapy. The trial was built on the European MMT-4 study (<LINK REF="STD-Carli-1999" TYPE="STUDY">Carli 1999</LINK>). In order to improve survival a new strategy was implemented; sequential and more up front multi-agent HDC, as a way to overcome drug resistance. However, the survival rate achieved in this study was only marginally better than in the previous European MMT-4 study (<LINK REF="STD-Carli-1999" TYPE="STUDY">Carli 1999</LINK>).</P>
<P>In a conference proceeding <LINK REF="STD-McDowell-2005" TYPE="STUDY">McDowell 2005</LINK> showed worse survival figures for patients treated with high-dose chemotherapy when compared to standard therapy. However, treatment allocation was purely centre-based. This might have introduced the risk of selection bias towards more high-risk patients in the high-dose treatment group. Characteristics of both treatment groups were not reported. The <LINK REF="STD-McDowell-2005" TYPE="STUDY">McDowell 2005</LINK> report is a conference proceeding, therefore a more detailed evaluation of this study will only be possible after a future publication of the full paper. </P>
<P>Where <LINK REF="STD-Klingebiel-2008" TYPE="STUDY">Klingebiel 2008</LINK> and <LINK REF="STD-Carli-1999" TYPE="STUDY">Carli 1999</LINK> used HDC as consolidation treatment, HDC was given early in the treatment schedule in the studies by <LINK REF="STD-Bisogno-2009" TYPE="STUDY">Bisogno 2009</LINK> and <LINK REF="STD-McDowell-2005" TYPE="STUDY">McDowell 2005</LINK>. This has several consequences. The first consequence of applying HDC early in treatment is that doses of chemotherapy are lower than in consolidation schedules. The reason is that in early HDC excessive myelosuppression and delay of subsequent therapies should be avoided. The second consequence is that most patients receiving early HDC will have evidence of disease, while those receiving high-dose consolidation treatment are only eligible when in complete remission at the time of HDC. This has important consequences for selection of patients. Patients receiving HDC in the studies by <LINK REF="STD-Klingebiel-2008" TYPE="STUDY">Klingebiel 2008</LINK> and <LINK REF="STD-Carli-1999" TYPE="STUDY">Carli 1999</LINK> might have a more favourable risk profile compared to those treated with high-dose in the studies by <LINK REF="STD-Bisogno-2009" TYPE="STUDY">Bisogno 2009</LINK> and <LINK REF="STD-McDowell-2005" TYPE="STUDY">McDowell 2005</LINK>. </P>
<P>Adverse effects were reported in detail by <LINK REF="STD-Klingebiel-2008" TYPE="STUDY">Klingebiel 2008</LINK>; grade 3-4 toxicity according to WHO occurred more often in the HDC- compared to the OT-group. Other studies (<LINK REF="STD-Carli-1999" TYPE="STUDY">Carli 1999</LINK>; <LINK REF="STD-Bisogno-2009" TYPE="STUDY">Bisogno 2009</LINK>) reported that toxicity in the HDC-group was comparable to previously published data in other tumour types. Very few patients died of treatment related toxicty and no differences between therapies were noted.</P>
<P>Based on the results of this systematic review, high-dose chemotherapy cannot be regarded as standard therapy for patients with stage IV RMS. Only a large prospective randomised controlled trial (RCT) could give definitive proof as to the value added by high-dose chemotherapy with stem cell transplantation. New patients with metastatic RMS should only be treated with high-dose chemotherapy when participating in such a prospective randomised controlled clinical trial.</P>
<P>However, results of the studies performed so far are not very encouraging, making it unlikely that a large randomised controlled trial testing the efficacy of high-dose mono-agent chemotherapy in this patient category will be performed in the near future. Considering the rarity of this disease, only one clinical hypothesis can be tested in large international clinical trials every five to 10 years. Nowadays new agents are becoming available for paediatric oncology, and more promising therapies, such as angiogenesis inhibitors, are more likely to be incorporated in future trials.  </P>
<P>In this systematic review we chose to include non-randomised studies because RCTs were not available. Non-randomised studies are not as reliable as randomised trials. In the field of paediatric oncology, however, randomised controlled clinical trials are relatively rare, partly because of the low incidence of conditions studied. Consequently, the best available evidence is often rendered by (controlled) clinical trials. An important limitation of non-RCTs is that selection bias cannot be ruled out. Furthermore publication bias also cannot be excluded.</P>
<P>With this systematic review we tried to answer the question of whether or not to use high-dose chemotherapy as a standard treatment for children with metastatic rhabdomyosarcoma. For now, there is no evidence to justify the standard use of high-dose chemotherapy in naive stage IV RMS patients.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Only one prospective controlled clinical trial (CCT) (<LINK REF="STD-Klingebiel-2008" TYPE="STUDY">Klingebiel 2008</LINK>), one historical CCT (<LINK REF="STD-Carli-1999" TYPE="STUDY">Carli 1999</LINK>) and one prospective single-arm study (including more than 20 patients) (<LINK REF="STD-Bisogno-2009" TYPE="STUDY">Bisogno 2009</LINK>) have been published. One unpublished CCT is awaiting assessment. Overall, the results of this systematic review do not justify the standard use of high-dose chemotherapy with stem cell transplantation in children with stage IV rhabdomyosarcoma.</P>
<P>In conclusion, new patients with stage IV RMS should only be treated with high-dose chemotherapy when participating in a large prospective randomised controlled clinical trial.</P>
<P>For patients with progressive disease or relapsed patients physicians should make a more individualised decision based on previous treatments and weighing possible benefits and therapy-related toxicities although very few data exist for the use of HDC in relapse (<LINK REF="REF-Weigel-2001" TYPE="REFERENCE">Weigel 2001</LINK>).</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Only a sufficiently powered and consequently large international prospective randomised controlled clinical trial will be able finally to answer the question of whether high-dose chemotherapy adds to survival in metastatic rhabdomyosarcoma patients. Since more promising therapies are available today, it does not seem to be very likely that such a trial will be conducted in the coming years.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank Leon Bax for translating a Japanese article, and Edith Leclercq (Trial Search Co-ordinator) for developing the search strategy and providing the titles/abstracts from the three electronic databases, Elvira van Dalen, MD PhD, as substitute Co-ordinating Editor and the editorial base of the Cochrane Childhood Cancer Group for their support. The editorial base of the Cochrane Childhood Cancer Group is funded by Kinderen Kankervrij (KIKA).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-07-23 11:36:45 +0200" MODIFIED_BY="[Empty name]">
<P>Gianni Bisogno is the first author of one of the included studies and co-author of this review. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<P>Conception and design: Rick Admiraal, Jasmijn Kobes, Leontien CM Kremer, Gianni Bisogno, Johannes HM Merks.</P>
<P>Data collection and analysis: Rick Admiraal, Marcel van der Paardt, Leontien CM Kremer, Johannes HM Merks.</P>
<P>Manuscript writing: Rick Admiraal, Marcel van der Paardt, Jasmijn Kobes, Leontien CM Kremer, Gianni Bisogno, Johannes HM Merks.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome measure 'median survival': since this is an infrequently used concept and is rarely, if ever, reported we only included event-free survival and overall survival as survival outcome measures.</P>
<P>Types of studies: as no randomised controlled trials were found, in addition to controlled clinical trials, we also searched for prospective non-controlled clinical trials including at least 20 naive metastatic rhabdomyosarcoma patients.</P>
<P>Since there were no randomised controlled trials included, and different aspects of the quality of the studies should be reported, we had to adjust the quality assessment criteria described in the original protocol. We assessed the quality of the articles (i.e. risk of selection bias, attrition bias, detection bias and performance bias) using various items.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bisogno-2009" MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Bisogno 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bisogno G, Ferrari A, Prete A, Messina C, Basso E, Cecchetto G, et al</AU>
<TI>Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma</TI>
<SO>European Journal of Cancer</SO>
<YR>2009</YR>
<VL>45</VL>
<PG>3035-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Carli-1999" MODIFIED="2009-06-22 16:59:25 +0200" MODIFIED_BY="[Empty name]" NAME="Carli 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-09-05 15:33:57 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carli M, Colombatti R, Oberlin O, Stevens M, Masiero L, Frascella E, et al</AU>
<TI>High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>9</NO>
<PG>2796-803</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Klingebiel-2008" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NAME="Klingebiel 2008" YEAR="April 2008">
<REFERENCE MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klingebiel T, Boos J, Beske F, Hallmen E, Int-Veen C, Dantonello T, et al</AU>
<TI>Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial</TI>
<SO>Pediatric Blood &amp; Cancer</SO>
<YR>2008</YR>
<VL>50</VL>
<NO>4</NO>
<PG>739-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-06-22 17:00:46 +0200" MODIFIED_BY="[Empty name]"/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aleinikova-2002" MODIFIED="2009-09-22 09:47:08 +0200" MODIFIED_BY="[Empty name]" NAME="Aleinikova 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-09-22 09:47:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aleinikova OV, Strongin YS, Pochetukhin KV</AU>
<TI>High-dose chemotherapy with autologous bone marrow transplantation in children with high-risk malignant neoformatioins</TI>
<SO>Voprosy Onkologii</SO>
<YR>2002</YR>
<VL>48</VL>
<NO>3</NO>
<PG>327-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Atra-2002" MODIFIED="2008-09-05 16:12:48 +0200" MODIFIED_BY="[Empty name]" NAME="Atra 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-09-05 16:12:48 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Atra A, Pinkerton R</AU>
<TI>High-dose chemotherapy in soft tissue sarcoma in children</TI>
<SO>Critical Reviews in Oncology/Hematology</SO>
<YR>2002</YR>
<VL>41</VL>
<PG>191-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bader-1989" MODIFIED="2009-09-21 13:12:29 +0200" MODIFIED_BY="[Empty name]" NAME="Bader 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-09-21 13:12:29 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bader JL, Horowitz ME, Dewan R, Watkins E, Triche TJ, Tsokos M, et al</AU>
<TI>Intensive combined modality therapy of small round cell and undifferentiated sarcomas in children and young adults: local control and patterns of failure</TI>
<SO>Radiotherapy &amp; Oncology</SO>
<YR>1989</YR>
<VL>16</VL>
<NO>3</NO>
<PG>189-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benchekroun-2008" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NAME="Benchekroun 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benchekroun S, Harif M, Madani A, Quessar A, Zafad S, Rachid R</AU>
<TI>Present and future of hematology and stem cell transplantation in Morocco</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2008</YR>
<VL>42</VL>
<PG>S106-S108</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bertuzzi-2002" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NAME="Bertuzzi 2002" YEAR="Apr 2002">
<REFERENCE MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bertuzzi A, Castagna L, Nozza A, Quagliuolo V, Siracusano L, Balzarotti M, et al</AU>
<TI>High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>8</NO>
<PG>2181-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blay-2000" MODIFIED="2009-09-21 14:38:12 +0200" MODIFIED_BY="[Empty name]" NAME="Blay 2000" YEAR="Nov 2000">
<REFERENCE MODIFIED="2009-09-21 14:38:12 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blay BJY, Bouhour D, Ray-Coquard I, Dumontet C, Philip T, Biron P</AU>
<TI>High-dose chemotherapy with autologous hemotapoietic stem cell transplantation for advanced soft tissue sarcoma in adults</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>21</NO>
<PG>3643-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bornbeck-2007" MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Bornbeck 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bornbeck B, Bahci S, Meisel R, Troeger R, Schonberger S</AU>
<TI>Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS)</TI>
<SO>Klinische Padiatrie</SO>
<YR>2007</YR>
<VL>219</VL>
<NO>6</NO>
<PG>318-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boulad-1998" MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Boulad 1998" YEAR="May 1998">
<REFERENCE MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boulad F, Kernan NA, LaQuaglia MP, Heller G, Lindsley KL, Rosenfield NS, et al</AU>
<TI>High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>5</NO>
<PG>1697-706</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Czyzewski-1999" MODIFIED="2009-12-02 16:16:03 +0100" MODIFIED_BY="[Empty name]" NAME="Czyzewski 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-12-02 16:16:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czyzewski EAD, Goldman S, Mundt AJ, Nachman J, Rubin C, Hallahan DE</AU>
<TI>Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and stem cell rescue</TI>
<SO>International Journal of Radiation, Oncology, Biology and Physics</SO>
<YR>1999</YR>
<VL>44</VL>
<NO>3</NO>
<PG>569-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diaz-1999" MODIFIED="2009-09-22 09:50:16 +0200" MODIFIED_BY="[Empty name]" NAME="Diaz 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-09-22 09:50:16 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diaz MA, Vicent MG, Madero L</AU>
<TI>High-dose busulfan/mephalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1999</YR>
<VL>24</VL>
<PG>1157-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donker-2009" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NAME="Donker 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donker AE, Hoogerbrugge PM, Mavinkurve-Groothuis AMC, van de Kar NCAJ</AU>
<TI>Metastatic rhabdomyosarcoma cured after chemotherapy and allogenic SCT</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2009</YR>
<VL>43</VL>
<PG>179-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ekert-1984" MODIFIED="2008-09-05 15:49:30 +0200" MODIFIED_BY="[Empty name]" NAME="Ekert 1984" YEAR="1984">
<REFERENCE MODIFIED="2008-09-05 15:49:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ekert H, Tiedemann K, Waters KD, Ellis WM</AU>
<TI>Experience with high dose multiagent chemotherapy and autologous bone marrow rescue in the treatment of twenty-two children with advanced tumours</TI>
<SO>Austrian Paediatric Journal</SO>
<YR>1984</YR>
<VL>20</VL>
<PG>195-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Endo-1996" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NAME="Endo 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Endo M, Yokoyama J, Ikawa H, Watanabe K, Ueda M, Kitajima M, et al</AU>
<TI>Treatment of high-risk solid tumors of childhood with myeloablative chemotherapy and autologous stem cell transplantation: a single institution experience</TI>
<SO>Oncology Reports</SO>
<YR>1996</YR>
<VL>3</VL>
<PG>519-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Foot-1997" MODIFIED="2008-09-06 21:57:12 +0200" MODIFIED_BY="[Empty name]" NAME="Foot 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-09-06 21:57:12 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Foot ABM, Pinkerton CR, Stevens M, Morland BJ, McDow HP</AU>
<TI>Sequential rapid high-dose single agent consolidation therapy for metastatic sarcoma in children</TI>
<SO>Proceedings SIOP Medical and Pediatric Oncology</SO>
<YR>1997</YR>
<VL>29</VL>
<PG>409</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fraser-2006" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NAME="Fraser 2006" YEAR="37">
<REFERENCE MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fraser CJ, Weigel BJ, Perentesis JP, Dusenbery KE, DeFor TE, Baker KS, et al</AU>
<TI>Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2006</YR>
<VL>37</VL>
<PG>175-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghavamdazeh-2009" MODIFIED="2009-09-21 13:15:24 +0200" MODIFIED_BY="[Empty name]" NAME="Ghavamdazeh 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-09-21 13:15:24 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghavamzadeh A, Alimogaddam K, Jahani M, Mousavi SA, Iravani M</AU>
<TI>Stem cell transplantation: Iranian experience</TI>
<SO>Archives of Iranian Medicine</SO>
<YR>2009</YR>
<VL>12</VL>
<PG>69-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Graham_x002d_Pole-1995" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NAME="Graham-Pole 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Graham-Pole J</AU>
<TI>Pediatric malignancies workshop - section on sarcomas and PNETs</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1995</YR>
<VL>15 (Suppl 1)</VL>
<PG>S247-S252</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gratwohl-2004" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NAME="Gratwohl 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gratwohl A, Baldomero H, Demirer T, Rosti G, Dini G, Ladenstein R, et al</AU>
<TI>Hemapoetic stem cell transplantation for solid tumors in Europe</TI>
<SO>Annals of Oncology</SO>
<YR>2004</YR>
<VL>15</VL>
<PG>653-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hara-1998" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NAME="Hara 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hara J, Osugi Y, Ohta H, Matsuda Y, Nakanishi K, Takai K, et al</AU>
<TI>Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1998</YR>
<VL>22</VL>
<PG>7-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hartmann-1986" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NAME="Hartmann 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hartman O, Benhamou E, Beaujean F, Pico JL, Kalifa C, Patte C, et al</AU>
<TI>High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: a phase II study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1986</YR>
<VL>4</VL>
<NO>12</NO>
<PG>1804-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hawkins-2002" MODIFIED="2010-09-20 12:26:15 +0200" MODIFIED_BY="[Empty name]" NAME="Hawkins 2002" YEAR="Sep 2002">
<REFERENCE MODIFIED="2010-09-20 12:26:15 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hawkins DS, Felgenhauer J, Park J, Kreissman S, Thomson B, Douglas J et al</AU>
<TI>Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas</TI>
<SO>Cancer</SO>
<YR>2002</YR>
<VL>95</VL>
<NO>6</NO>
<PG>1354-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horowitz-1993" MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Horowitz 1993" YEAR="October 1993">
<REFERENCE MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horowitz ME, Kinsella TJ, Wexler LH, Belasco J, Triche T, Tsokos M, et al</AU>
<TI>Total body irradiation and autologous bone marrow transplantation in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1993</YR>
<VL>11</VL>
<NO>10</NO>
<PG>1911-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hosoi-2007" MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Hosoi 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hosoi H, Teramukai S, Matsumoto Y, Tsuchiya K, Iehara T, Hara J, et al</AU>
<TI>A review of 331 rhabdomyosarcoma cases in patients treated between 1991 and 2002 in Japan</TI>
<SO>International Journal of Clinical Oncology</SO>
<YR>2007</YR>
<VL>12</VL>
<NO>2</NO>
<PG>137-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kasper-2004" MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Kasper 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kasper B, Lehnert T, Bernd L, Mechtersheimer G, Goldschmidt H, Ho AD, et al</AU>
<TI>High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft tissue sarcomas</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2004</YR>
<VL>34</VL>
<PG>37-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kavan-1997" MODIFIED="2008-09-06 18:33:01 +0200" MODIFIED_BY="[Empty name]" NAME="Kavan 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-09-06 18:33:01 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kavan P, Stankova J, Koutecky J, Gajdos P</AU>
<TI>High dose chemotherapy with subsequent autologous stem cell transplantation in children and adolescents for high-risk rhabdomyosarcoma</TI>
<TO>Vysokodavkovana terapie s naslednou autologni transplantaci hematopoeticky kmenovych bunek u deti a mladistvychs rabdomyosarkomem vysokeho rizika. Vysledky trileteho prezivani</TO>
<SO>Klincka Onkologie</SO>
<YR>1997</YR>
<VL>10</VL>
<NO>5</NO>
<PG>148-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kazanowska-1997" MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Kazanowska 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kazanowska B, Boguslawska-Jaworska J, Rosinska B, Czernik J, Jaworski W, Jelen , et al</AU>
<TI>Results of soft tissue sarcoma therapy in children treated according to CWS-91 and SIOP-IV-intergroup study</TI>
<TO>Wyniki leczenia miesaka tkanek miekkich u dziece leczonych wedlug CWS-91 i SIOP-IV-Intergroup Study. Raport Polskiej Pediatrycznej Grupy Guzow Litych</TO>
<SO>Pediatria Polska</SO>
<YR>1997</YR>
<VL>72</VL>
<NO>10</NO>
<PG>897-903</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinsella-1988" MODIFIED="2008-09-06 18:29:34 +0200" MODIFIED_BY="[Empty name]" NAME="Kinsella 1988" YEAR="1988">
<REFERENCE MODIFIED="2008-09-06 18:29:34 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinsella TJ, Miser JS, Triche TJ, Horvath K, Glatstein E</AU>
<TI>Treatment of high-risk sarcomas in children and young adults: analysis of local control using intensive combined modality therapy</TI>
<SO>NCI Monographs</SO>
<YR>1988</YR>
<VL>6</VL>
<PG>291-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koscielniak-1997" MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Koscielniak 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koscielniak E, Klingebiel TH, Peters C, Hermann J, Burdach ST, Bender-Gotze C, et al</AU>
<TI>Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1997</YR>
<VL>19</VL>
<PG>227-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuhne-2000" MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Kuhne 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuhne T, Staehelin F, Avolede P, Tichelli A, Passweg J, Imbach P, et al</AU>
<TI>Single and double high-dose chemotherapy with autologous stem cell transplantation in children with advanced solid tumors: first experience</TI>
<TO>Einfache und doppelte Hochdosis-Chemotherapie mit autologer Stammzelltransplantation bei Kindern mit fortgeschrittenen soliden Tumoren: erste Erfahrungen</TO>
<SO>Schweizer Medizinal Wochenschrift</SO>
<YR>2000</YR>
<VL>130</VL>
<PG>419-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ladenstein-1997" MODIFIED="2009-09-21 14:40:34 +0200" MODIFIED_BY="[Empty name]" NAME="Ladenstein 1997" YEAR="Feb 1997">
<REFERENCE MODIFIED="2009-09-21 14:40:34 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ladenstein R, Philip T, Gardner H</AU>
<TI>Autologous stem cell transplantation for solid tumors in children</TI>
<SO>Current Opinion in Pediatrics</SO>
<YR>1997</YR>
<VL>9</VL>
<NO>1</NO>
<PG>55-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lafay_x002d_Cousin-2000" MODIFIED="2008-09-06 18:19:55 +0200" MODIFIED_BY="[Empty name]" NAME="Lafay-Cousin 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-09-06 18:19:55 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lafay-Cousin L, Hartmann O, Plouvier P, Mechinaud F, Boutard P, Oberlin O</AU>
<TI>High-dose thiotepa and hematopoietic stem cell transplantation in pediatric malignant mesenchymal tumors: a phase II study</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2000</YR>
<VL>26</VL>
<PG>627-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mackall-2008" MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Mackall 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mackall C, Baird K, Love C, Wayne A, Fry T</AU>
<TI>Prolonged survival in patients with ultra high-risk pediatric sarcomas following reduced intensity allogeneic peripheral blood stem cell transplantation</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>15S</NO>
<PG>21000</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matsubara-2003" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NAME="Matsubara 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matsubara H, Makimoto A, Higa T, Kawamoto H, Takayama J, Ohira M, et al</AU>
<TI>Possible benefits of high-dose chemotherapy as intensive consolidation in patients with high-risk rhabdomyosarcoma who achieve complete remission with conventional chemotherapy</TI>
<SO>Pediatric Hematology and Oncology</SO>
<YR>2003</YR>
<VL>20</VL>
<PG>201-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Melagolowkin-1999" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NAME="Melagolowkin 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malogolowkin M</AU>
<TI>Lack of improvement in survival of children with metastatic rhabdomyosarcoma treated with intensive therapy followed by stem cell transplant for control of minimal residual disease</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>1999</YR>
<VL>18</VL>
<PG>555</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Navid-2006" MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Navid 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Navid F, Santana VM, Billups CA, Merchant TE, Furman WL, Spunt SL, et al</AU>
<TI>Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide for high-risk sarcomas</TI>
<SO>Cancer</SO>
<YR>2006</YR>
<VL>106</VL>
<PG>1846-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohira-1990" MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Ohira 1990" YEAR="Dec 1990">
<REFERENCE MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohira M</AU>
<TI>Autologous bone marrow transplantation for pediatric cancer</TI>
<SO>Gan To Kagaku Ryoho. Cancer &amp; Chemotherapy</SO>
<YR>1990</YR>
<VL>17</VL>
<NO>12</NO>
<PG>2299-306</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oue-2003" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NAME="Oue 2003" YEAR="Jan 2003">
<REFERENCE MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oue T, Kubota A, Okuyama H, Kawahara H, Inoue M, Yagi K, et al</AU>
<TI>Megatherapy with hemotopoeitic stem cell rescue as a preoperative treatment in unresectable pediatric malignancies</TI>
<SO>Journal of Pediatric Surgery</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>1</NO>
<PG>130-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perentesis-1999" MODIFIED="2008-09-06 18:21:15 +0200" MODIFIED_BY="[Empty name]" NAME="Perentesis 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-09-06 18:21:15 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perentesis JP, Katsanis E, DeFor TE, Neglia JP, Ramsay NKC</AU>
<TI>Autologous stem cell transplantation for high risk pediatric solid tumours</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1999</YR>
<VL>24</VL>
<PG>609-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pession-1999" MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Pession 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pession A, Prete A, Locatelli F, Bella S, Melchionda F, Garaventa A, et al</AU>
<TI>Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors</TI>
<SO>Medical and Pediatric Oncology</SO>
<YR>1999</YR>
<VL>33</VL>
<PG>450-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pico-1993" MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Pico 1993" YEAR="Nov 1993">
<REFERENCE MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pico JL, Ibrahim A, Castagna L, Bourhis JH, Chazard M, Maraninchi D, et al</AU>
<TI>Escalating high-dose carboplatin and autologous bone marrow transplantation in solid tumors</TI>
<SO>Oncology</SO>
<YR>1993</YR>
<VL>50 (Suppl 2)</VL>
<PG>47-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pinkerton-1991_x002d_2" MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Pinkerton 1991-2" YEAR="Aug 1991">
<REFERENCE MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pinkerton CR, Groot-Loonen J, Barrett A, Meller ST, Tait D, Ashley S, et al</AU>
<TI>Rapid VAC high dose melphalan regimen, a novel chemotherapy approach in children with soft tissue sarcomas</TI>
<SO>British Journal of Cancer</SO>
<YR>1991</YR>
<VL>64</VL>
<NO>2</NO>
<PG>381-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosti-2002" MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Rosti 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosti G, Ferrante P, Ledermann J, Leyvraz S, Ladenstein R, Kocsielniak E, et al</AU>
<TI>High-dose chemotherapy for solid tumors: result of the EBMT</TI>
<SO>Critical Reviews in Oncology/Hematology</SO>
<YR>2002</YR>
<VL>41</VL>
<PG>129-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rzepecki-2006" MODIFIED="2008-09-05 16:21:49 +0200" MODIFIED_BY="[Empty name]" NAME="Rzepecki 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-09-05 16:21:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rzepecki P, Sarosiek T, Szczylik C</AU>
<TI>Autologous hematopoietic cell transplantation in adult patients with germ cell tumors and soft tissue sarcomas</TI>
<TO>Rola przeszczepienia autologicznych krwiotworczych komorek macierzystych w leczeniu guzow zarodkowych oraz miesakow tkanek miekkich</TO>
<SO>Wspoczesna Onkologia</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>1</NO>
<PG>7-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stea-1987" MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Stea 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stea B, Kinsella TJ, Triche TJ, Horvath K, Glatstein E, Miser JS</AU>
<TI>Treatment of pelvic sarcomas in adolescents and young adults with intensive combined modality therapy</TI>
<SO>Internal Journal of Radiation Oncology, Biology and Physics</SO>
<YR>1987</YR>
<VL>13</VL>
<PG>1797-805</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walterhouse-1999" MODIFIED="2009-09-21 14:43:27 +0200" MODIFIED_BY="[Empty name]" NAME="Walterhouse 1999" YEAR="Feb 1999">
<REFERENCE MODIFIED="2009-09-21 14:43:27 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walterhouse DO, Hoover ML, Marymont MA, Kletzel M</AU>
<TI>High-dose chemotherapy followed by peripheral blood stem cell rescue for metastatic rhabdomyosarcoma: the experience at Chicago Children's Memorial Hospital</TI>
<SO>Medical Pediatric Oncology</SO>
<YR>1999</YR>
<VL>32</VL>
<NO>2</NO>
<PG>88-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Williams-2004" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NAME="Williams 2004" YEAR="Apr 2004">
<REFERENCE MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Williams BA, Williams KM, Doyle J, Stephens D, Greenberg M, Malkin D, et al</AU>
<TI>Metastatic rhabdomyosarcoma: a retrospective review of patients treated at the Hospital for Sick Children between 1989 and 1999</TI>
<SO>Journal of Pediatric Hematology and Oncology</SO>
<YR>2004</YR>
<VL>26</VL>
<NO>4</NO>
<PG>243-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamada-2007" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NAME="Yamada 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamada K, Takahashi M, Ogura M, Kagami Y, Taji H, Kamiya Y, et al</AU>
<TI>High-dose chemotherapy and autologous peripheral blood stem cell transfusion for adult and adolescent patients with small round cell sarcomas</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2007</YR>
<VL>39</VL>
<NO>8</NO>
<PG>471-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-12-20 12:54:06 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="SOUGHT" ID="STD-McDowell-2005" MODIFIED="2009-06-22 16:55:47 +0200" MODIFIED_BY="[Empty name]" NAME="McDowell 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-06-22 16:55:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>McDowell H, Foot A, Bergeron C, Jenney M, Stevens M, Oberlin O, et al</AU>
<TI>Metastatic rhabdomyosarcoma report: SIOP trial MMT98</TI>
<SO>Pediatric Blood and Cancer</SO>
<YR>2005</YR>
<VL>45</VL>
<NO>4</NO>
<PG>411</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2009-06-22 16:55:47 +0200" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Breneman-2003" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NAME="Breneman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM, et al</AU>
<TI>Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma - a report from the Intergroup Rhabdomyosarcoma Study IV</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>1</NO>
<PG>78-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carli-2004" NAME="Carli 2004" TYPE="JOURNAL_ARTICLE">
<AU>Carli M, Colombattti R, Oberlin O, Bisogno G, Treuner J, Koscielniak E, et al</AU>
<TI>European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma; final results and analysis of prognostic factors</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>4787-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crist-2001" NAME="Crist 2001" TYPE="JOURNAL_ARTICLE">
<AU>Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, et al</AU>
<TI>Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>12</NO>
<PG>3091-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dumontet-1992" NAME="Dumontet 1992" TYPE="JOURNAL_ARTICLE">
<AU>Dumontet C, Biron P, Bouffet E, Blay JY, Meckenstock R, Chauvin F, et al</AU>
<TI>High dose chemotherapy with ABMT in soft tissue sarcomas: a report of 22 cases</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1992</YR>
<VL>10</VL>
<NO>5</NO>
<PG>405-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fraser-2006" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NAME="Fraser 2006" TYPE="JOURNAL_ARTICLE">
<AU>Fraser CJ, Weigel BJ, Perentesis JP, Dusenbery KE, DeFor TE, et al</AU>
<TI>Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2006</YR>
<VL>37</VL>
<NO>2</NO>
<PG>175-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grovas-1997" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NAME="Grovas 1997" TYPE="JOURNAL_ARTICLE">
<AU>Grovas A, Fremgen A, Rauck A, Ruymann FB, Hutchinson CL, Winchester DP, et al</AU>
<TI>The national cancer database report on patterns of childhood cancers in the United States</TI>
<SO>Cancer</SO>
<YR>1997</YR>
<VL>80</VL>
<NO>12</NO>
<PG>2321-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hartmann-1991" NAME="Hartmann 1991" TYPE="JOURNAL_ARTICLE">
<AU>Hartmann O, Vassal G, Valteau D, Brugieres L, Lemerle J</AU>
<TI>Autologous bone marrow transplantation in pediatric solid tumors: phase II studies</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1991</YR>
<VL>7</VL>
<NO>3</NO>
<PG>106-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" NAME="Higgins 2005" TYPE="BOOK">
<AU>Higgins JPT, Green S, editors</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2006</SO>
<YR>2006</YR>
<PB>John Wiley &amp; Sons Ltd</PB>
<CY>Chichester (UK)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-2008" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NAME="Lee 2008" TYPE="JOURNAL_ARTICLE">
<AU>Lee SH, Yoo KH, Sung KW, Kim JY, Cho EJ, Koo HH, et al</AU>
<TI>Tandem high-dose chemotherapy and autologous stem cell rescue in children with bilateral advanced retinoblastoma</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2008</YR>
<VL>42</VL>
<NO>6</NO>
<PG>385-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matthay-1999" NAME="Matthay 1999" TYPE="JOURNAL_ARTICLE">
<AU>Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al</AU>
<TI>Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<NO>16</NO>
<PG>1165-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oberlin-2008" MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Oberlin 2008" TYPE="JOURNAL_ARTICLE">
<AU>Oberlin O, Rey A, Lyden E, Bisogno G, Stevens MC, Meyer WH, et al</AU>
<TI>Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups</TI>
<SO>Journal of Clininical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>14</NO>
<PG>2384-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pinkerton-1991" NAME="Pinkerton 1991" TYPE="JOURNAL_ARTICLE">
<AU>Pinkerton CR</AU>
<TI>Megatherapy for soft tissue sarcomas. EBMT experience</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1991</YR>
<VL>7</VL>
<NO>3</NO>
<PG>120-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosenthal-2008" MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Rosenthal 2008" TYPE="JOURNAL_ARTICLE">
<AU>Rosenthal J, Bolotin E, Shakhnovits M, Pawlowska A, Falk P, Qian D, et al</AU>
<TI>High-dose therapy with hematopoietic stem cell rescue in patients with poor prognosis Ewing family tumors</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2008</YR>
<VL>42</VL>
<NO>5</NO>
<PG>311-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spreafico-2008" MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Spreafico 2008" TYPE="JOURNAL_ARTICLE">
<AU>Spreafico F, Bisogno G, Collini P, Jenkner A, Gandola L, D'Angelo P, et al</AU>
<TI>Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem cell support: experience by the Italian Association of Pediatric Hematology and Oncology</TI>
<SO>Pediatric Blood and Cancer</SO>
<YR>2008</YR>
<VL>51</VL>
<NO>1</NO>
<PG>23-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stevens-2005" MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Stevens 2005" TYPE="JOURNAL_ARTICLE">
<AU>Stevens MC, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, et al</AU>
<TI>Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology - SIOP Malignant Mesenchymal Tumor 89</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>12</NO>
<PG>2618-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stiller-1994" NAME="Stiller 1994" TYPE="JOURNAL_ARTICLE">
<AU>Stiller CA, Parkin DM</AU>
<TI>International variations in the incidence of childhood soft-tissue sarcomas</TI>
<SO>Paediatric and Perinatal Epidemiology</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>1</NO>
<PG>107-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weigel-2001" MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Weigel 2001" TYPE="JOURNAL_ARTICLE">
<AU>Weigel BJ, Breitfield P, Hawkins D, Crist WM, William M, Baker K, et al</AU>
<TI>Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma</TI>
<SO>Journal of Pediatric Hematology/Oncology</SO>
<YR>2001</YR>
<VL>23</VL>
<NO>5</NO>
<PG>272-6</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" SORT_BY="USER" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" ORDER="52" STUDY_ID="STD-Klingebiel-2008">
<CHAR_METHODS MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective controlled clinical trial</P>
<P>European multicentre study</P>
<P>Allocation of treatment based on physician's decision</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>258 patients &lt; 22 years of age registered in the CWS-96 study with sufficient treatment data present</P>
<P>162 patients did not receive scheduled treatment and were excluded</P>
<P>96 (74 rhabdomyosarcoma) patients were treated with high-dose chemotherapy (HDC) or oral treatment (OT)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>34/74 patients were treated in the HDC arm</P>
<P>Pre-treatment with 7 courses of CEVAIE</P>
<P>High-dose chemotherapy consisting of thiotepa, cyclophosfamide, melphalan and etoposide followed by autologous stem cell transplantation</P>
<P>40/74 patients were treated in the OT arm</P>
<P>Pre-treatment with 9 courses of CEVAIE</P>
<P>Oral maintenance consisting of trofosfamide and etoposide alternating with trofosfamide and idarubicin in 4 cycles in 22 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Overall survival was calculated as the period between first diagnosis and death</P>
<P>Event-free survival was defined as the time between first diagnosis and death, progression or local and/or metastatic relapse</P>
<P>Toxicity was graded and registered according to WHO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Median follow up was 57.4 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" ORDER="53" STUDY_ID="STD-Carli-1999">
<CHAR_METHODS MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective historical controlled clinical trial</P>
<P>European multicentre study</P>
<P>Allocation of treatment  based on time of diagnosis and centre-based choice to treat all patients either with high-dose chemotherapy (HDC) or standard therapy (ST)</P>
<P>High-dose chemotherapy: </P>
<P>- diagnosis between 1991-1995 (MMT4-91): (n = 52)</P>
<P>Standard therapy:</P>
<P>- diagnosis between 1989-1991 (MMT4-89):(n = 24/44)</P>
<P>- diagnosis between 1991-1995 and treated in centres not performing HDC (n = 20/44)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-02 15:52:45 +0100" MODIFIED_BY="[Empty name]">
<P>96 children aged 3 months to 18 years in clinical complete remission before the third cycle, of an original cohort of 174 children with stage IV RMS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>52/96 patients : HDC</P>
<P>Pretreatment: 3 cycles (9 courses) of intensive multi-agent chemotherapy (CEVAIE)</P>
<P>Details HDC: 42 melphalan alone, 10 different combinations</P>
<P>44/96 patients: ST</P>
<P>Pretreatment: 3 cycles of intensive multi-agent chemotherapy (CEVAIE)</P>
<P>Details ST: 1 additional cycle of intensive multi-agent chemotherapy (CEVAIE)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Event-free survival was calculated from the interval between diagnosis and the date of first progression, relapse or death as a result of any cause</P>
<P>Overall survival was calculated from the time interval between the date of diagnosis and the date of last follow up or death</P>
<P>Toxicity was registered according to Common Toxicity Criteria</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Median follow up 8 years</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" ORDER="54" STUDY_ID="STD-Bisogno-2009">
<CHAR_METHODS MODIFIED="2010-05-01 10:50:38 +0200" MODIFIED_BY="[Empty name]">
<P>Prospective non-controlled clinical trial</P>
<P>Italian multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>70 children with metastatic RMS aged 0.9 months to 20.9 years in clinical complete or partial remission after induction chemotherapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Induction chemotherapy:</P>
<P>30/70 patients: 1 cycle (3 courses) of CEVAIE</P>
<P>40/70 patients: 1 cycle (3 courses) of IVADo</P>
<P>High-dose chemotherapy:</P>
<P>62/70 patients: 4 cycles of HDC consisting of cyclophosphamide, etoposide, thiotepa and melphalan</P>
<P>Maintenance chemotherapy:</P>
<P>41/70 patients: 6 cycles of VAC</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Event-free survival was calculated from the interval between diagnosis and the date of first progression, relapse or death as a result of any cause</P>
<P>Overall survival was calculated from the time interval between the date of diagnosis and the date of last follow up or death</P>
<P>Toxicity was registered according to Common Toxicity Criteria</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-20 14:16:04 +0100" MODIFIED_BY="[Empty name]">
<P>Median follow up was 5 years</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CEVAIE: carboplatin, epirubicin, vincristine, actinomycin, ifosfamide, etoposide<BR/>EFS: event-free survival<BR/>HDC: high-dose chemotherapy<BR/>IVADo: ifosfamide, vincristine, actinomycin, doxorubicin<BR/>OT: oral treatment<BR/>ST: standard therapy<BR/>VAC: vincristine, actinomycin, cyclophosphamide<BR/>WHO: World Health Organization<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-12-02 15:57:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aleinikova-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-02 15:57:59 +0100" MODIFIED_BY="[Empty name]">
<P>Review, no new patients included in addition to those reported in the reviewed studies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-02 15:58:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Atra-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-02 15:58:02 +0100" MODIFIED_BY="[Empty name]">
<P>Review, no new patients included in addition to those reported in the reviewed studies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bader-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>No treatment with high-dose chemotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Benchekroun-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bertuzzi-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blay-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bornbeck-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boulad-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Czyzewski-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Diaz-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Donker-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ekert-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Endo-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Foot-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fraser-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ghavamdazeh-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-02 15:58:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Graham_x002d_Pole-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-02 15:58:25 +0100" MODIFIED_BY="[Empty name]">
<P>Review, no new patients included in addition to those reported in the reviewed studies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-02 15:58:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gratwohl-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-02 15:58:27 +0100" MODIFIED_BY="[Empty name]">
<P>Review, no new patients included in addition to those reported in the reviewed studies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hara-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hartmann-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hawkins-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Horowitz-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-03 22:22:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hosoi-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-03 22:22:32 +0200" MODIFIED_BY="[Empty name]">
<P>Retrospective case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kasper-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kavan-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kazanowska-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kinsella-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-03 22:22:40 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koscielniak-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-03 22:22:40 +0200" MODIFIED_BY="[Empty name]">
<P>Retrospective case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuhne-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-02 15:58:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ladenstein-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-02 15:58:35 +0100" MODIFIED_BY="[Empty name]">
<P>Review, no new patients included in addition to those reported in the reviewed studies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lafay_x002d_Cousin-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mackall-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matsubara-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Melagolowkin-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Navid-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ohira-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oue-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Perentesis-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pession-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pico-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pinkerton-1991_x002d_2">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-02 15:58:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rosti-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-02 15:58:41 +0100" MODIFIED_BY="[Empty name]">
<P>Review, no new patients included in addition to those reported in the reviewed studies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rzepecki-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stea-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>No treatment with high-dose chemotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Walterhouse-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Williams-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yamada-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fewer than 20 patients with stage IV RMS included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RMS: rhabdomyosarcoma</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" SORT_BY="USER" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" ORDER="102" STUDY_ID="STD-McDowell-2005">
<CHAR_METHODS MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective controlled clinical trial</P>
<P>European multicentre study</P>
<P>1998 to 2004</P>
<P>Allocation of treatment: centre-based choice: patients treated in centres able to perform high-dose chemotherapy (HDC) were treated with HDC</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-06-22 16:55:47 +0200" MODIFIED_BY="[Empty name]">
<P>74 children with high risk (HR) metastatic RMS out of a total cohort of 112 children with metastatic RMS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>46/74 HR patients: HDC</P>
<P>Details HDC: window + high-dose sequential mono therapy (HDSMT) + autologous stem cell transplantation followed by VAC maintenance</P>
<P>28/74 HR patients: ST</P>
<P>Details ST: 6-drug standard-dose chemotherapy followed by VAC maintenance</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Event-free survival: definition not given</P>
<P>Overall survival: definition not given</P>
<P>Toxicity: not mentioned</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Median follow up 11.4 months</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>RMS: rhabdomyosarcoma<BR/>VAC: Vincristine, Actinomycin, Cyclophosphamide</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-06-22 16:55:47 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-04-03 11:40:05 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-04-03 11:36:54 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-04-03 11:36:54 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-04-03 11:36:54 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>mortality</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-05-26 15:45:01 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-06-22 17:02:15 +0200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Randomised controlled trial?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bisogno-2009">
<DESCRIPTION>
<P>Prospective non-controlled clinical trial (single-arm)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carli-1999">
<DESCRIPTION>
<P>Prospective historical controlled clinical trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Klingebiel-2008">
<DESCRIPTION>
<P>Prospective controlled clinical trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Controlled clinical trial?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bisogno-2009">
<DESCRIPTION>
<P>Prospective non-controlled clinical trial (single-arm)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carli-1999">
<DESCRIPTION>
<P>Prospective historical controlled clinical trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klingebiel-2008">
<DESCRIPTION>
<P>Prospective controlled clinical trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2010-09-20 12:13:33 +0200" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Consecutive patients in the study group?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-20 12:13:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bisogno-2009">
<DESCRIPTION>
<P>Consecutive patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-20 12:12:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carli-1999">
<DESCRIPTION>
<P>Consecutive patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-20 12:09:00 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klingebiel-2008">
<DESCRIPTION>
<P>Consecutive patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2010-09-20 12:12:05 +0200" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Consecutive patients in the control group?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-03 18:13:44 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bisogno-2009">
<DESCRIPTION>
<P>No control group, not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-20 12:12:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carli-1999">
<DESCRIPTION>
<P>Consecutive patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-20 12:09:01 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klingebiel-2008">
<DESCRIPTION>
<P>Consecutive patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Comparability?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-03 18:13:22 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bisogno-2009">
<DESCRIPTION>
<P>No control group, not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carli-1999">
<DESCRIPTION>
<P>Patients from the study and control group are from the same cohort and/or risk factors are equally distributed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-20 13:05:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klingebiel-2008">
<DESCRIPTION>
<P>Patients in study group and control group are from the same cohort and/or risk factors are equally distributed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2010-09-20 12:10:11 +0200" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Low risk of performance bias?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-23 11:21:50 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bisogno-2009">
<DESCRIPTION>
<P>No control group, not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-23 11:18:46 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carli-1999">
<DESCRIPTION>
<P>No blinding of patient and care provider</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-23 11:18:34 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Klingebiel-2008">
<DESCRIPTION>
<P>No blinding of patient and care provider</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="STUDY" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Low risk of selection bias?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-23 11:14:40 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bisogno-2009">
<DESCRIPTION>
<P>No control group, not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carli-1999">
<DESCRIPTION>
<P>Centre-based randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-23 11:15:48 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Klingebiel-2008">
<DESCRIPTION>
<P>Allocation based on physician's decision</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-15" LEVEL="STUDY" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NO="15">
<NAME>Low risk of attrition bias?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bisogno-2009">
<DESCRIPTION>
<P>Assessment of all outcomes in all patients</P>
<P>All patients included in the study are analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-20 12:12:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carli-1999">
<DESCRIPTION>
<P>Assessment of all outcomes in all patients</P>
<P>All patients included in the study are analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Klingebiel-2008">
<DESCRIPTION>
<P>Assessment of all outcomes was not performed in all patients</P>
<P>Not all patients included in the study were analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-16" LEVEL="STUDY" MODIFIED="2010-09-20 12:09:36 +0200" MODIFIED_BY="[Empty name]" NO="16">
<NAME>Low risk of detection bias?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-23 11:21:20 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bisogno-2009">
<DESCRIPTION>
<P>No blinding of outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-03 18:30:44 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carli-1999">
<DESCRIPTION>
<P>No blinding of outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-03 18:42:18 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Klingebiel-2008">
<DESCRIPTION>
<P>No blinding of outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2010-04-03 11:29:25 +0200" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2010-11-04 22:35:42 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-09-20 12:20:40 +0200" MODIFIED_BY="[Empty name]">External validity study/control group, intervention, follow up and outcome</TITLE>
<TABLE COLS="4" ROWS="7">
<TR>
<TH VALIGN="BOTTOM">
<P/>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Klingebiel 2008</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Carli 1999</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Bisogno 2009</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Study group well described: </B>
</P>
<P>Description of age, number of metastatic sites, bone/bone marrow metastases, primary tumour localisation</P>
<P>+ = 3 or 4 items; &#8776; = 2 items; - = 0 or 1 item</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Control group well described: </B>
</P>
<P>Description of age, number of metastatic sites, bone/bone marrow metastases, primary tumour localisation</P>
<P>+ = 3 items; &#8776; = 2 items; - = 0 or 1 item</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>No control group</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Study group intervention well described:</B>
</P>
<P>Type of chemotherapy, dosage, local treatment, type of transplant</P>
<P>+ = 3 or 4 items; &#8776; = 2 items; - = 0 or 1 item</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Control group intervention well described:</B>
</P>
<P>Type of chemotherapy, dosage, local treatment</P>
<P>+ = 3 items; &#8776; = 2 items; - = 0 or 1 item</P>
</TD>
<TD ALIGN="CENTER">
<P>&#8776;</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>No control group</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Follow up well described:</B>
</P>
<P>Minimal follow up described = +</P>
<P>Minimal follow up not described = -</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Outcome well described:</B>
</P>
<P>Outcome measurement well described (EFS/OS/toxicity) = +</P>
<P>Outcome measurement not well described (EFS/OS/toxicity) = -</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>EFS: event-free survival<BR/>OS: overall survival</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-09-20 12:34:22 +0200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-09-20 12:34:22 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>High-dose chemotherapy and stem cell rescue versus standard-dose chemotherapy</NAME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.01" MODIFIED="2010-09-20 12:34:22 +0200" MODIFIED_BY="[Empty name]" NO="1" ROWS_PER_STUDY="3" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES">
<NAME>Event-free survival (EFS), overall survival (OS) and adverse effects</NAME>
<TR>
<TH>
<P>Outcome</P>
<P>definition</P>
</TH>
<TH>
<P>Treatment arm</P>
</TH>
<TH>
<P>Control arm</P>
</TH>
<TH>
<P>P value</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.01.01" MODIFIED="2010-05-02 10:31:42 +0200" MODIFIED_BY="[Empty name]" NO="1" STUDIES="3">
<NAME>All patients</NAME>
<OTHER_DATA MODIFIED="2010-05-02 10:31:42 +0200" MODIFIED_BY="[Empty name]" ORDER="6" STUDY_ID="STD-Bisogno-2009">
<TR>
<TD>
<P>3-years PFS</P>
</TD>
<TD>
<P>N=62</P>
<P>35.3% (95% CI: 24-47%)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>3-years OS</P>
</TD>
<TD>
<P>42.3% (95% CI: 31-54%)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Toxic death</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2010-04-23 21:02:03 +0200" MODIFIED_BY="[Empty name]" ORDER="7" STUDY_ID="STD-Carli-1999">
<TR>
<TD>
<P>5-years EFS</P>
</TD>
<TD>
<P>N=52</P>
<P>29% (95%CI: 16-41%)</P>
</TD>
<TD>
<P>N=44</P>
<P>23% (95%CI: 11-36%)</P>
</TD>
<TD>
<P>0.3</P>
</TD>
</TR>
<TR>
<TD>
<P>5-years OS</P>
</TD>
<TD>
<P>36% (95%CI: 16-41%)</P>
</TD>
<TD>
<P>27% (95%CI: 14-41%)</P>
</TD>
<TD>
<P>0.2</P>
</TD>
</TR>
<TR>
<TD>
<P>Toxic death</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2010-04-21 21:30:40 +0200" MODIFIED_BY="[Empty name]" ORDER="8" STUDY_ID="STD-Klingebiel-2008">
<TR>
<TD>
<P>5-years EFS</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>5-years OS</P>
</TD>
<TD>
<P>N=34</P>
<P>15% (95%CI: 3-27%)</P>
</TD>
<TD>
<P>N=40</P>
<P>52% (95%CI: 34-68%)</P>
</TD>
<TD>
<P>&lt;0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>Toxic death</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.01.02" MODIFIED="2010-04-21 21:47:24 +0200" MODIFIED_BY="[Empty name]" NO="2" STUDIES="1">
<NAME>Patients without bone or BM disease</NAME>
<OTHER_DATA MODIFIED="2010-04-21 21:47:24 +0200" MODIFIED_BY="[Empty name]" ORDER="9" STUDY_ID="STD-Klingebiel-2008">
<TR>
<TD>
<P>5-years OS</P>
</TD>
<TD>
<P>N=20</P>
<P>40% (95%CI: 19-61%)</P>
</TD>
<TD>
<P>n=31</P>
<P>73% (95%CI: 57-89%)</P>
</TD>
<TD>
<P>0.04</P>
</TD>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.01.03" MODIFIED="2010-09-20 12:34:22 +0200" MODIFIED_BY="[Empty name]" NO="3" STUDIES="1">
<NAME>High-risk patients with BM and/or bone involvement</NAME>
<OTHER_DATA MODIFIED="2010-05-02 10:32:36 +0200" MODIFIED_BY="[Empty name]" ORDER="10" STUDY_ID="STD-Klingebiel-2008">
<TR>
<TD>
<P>5-years OS</P>
</TD>
<TD>
<P>N=24</P>
<P>13% (95%CI: 1-25%)</P>
</TD>
<TD>
<P>N=19</P>
<P>17% (95%CI: 1-33%)</P>
</TD>
<TD>
<P>0.75</P>
</TD>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-11-04 22:35:44 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-11-04 22:35:44 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAX0AAAFZCAIAAAD7JmgmAAARBElEQVR42u3dP44USRPG4T7AGBgc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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-07-23 11:46:02 +0200" MODIFIED_BY="[Empty name]">Details of excluded studies</TITLE>
<APPENDIX_BODY MODIFIED="2010-11-04 22:35:43 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="6" ROWS="50">
<TR>
<TH VALIGN="BOTTOM">
<P>First author</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Reason for exclusion</P>
</TH>
<TH VALIGN="BOTTOM">
<P>N of patients with stage IV RMS and received high-dose chemotherapy</P>
</TH>
<TH VALIGN="BOTTOM">
<P>CS/RE*</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Type of high-dose chemotherapy &#8224;</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Total body irradiation</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hosoi-2007" TYPE="STUDY">Hosoi 2007</LINK>
</P>
</TD>
<TD>
<P>Retrospective</P>
</TD>
<TD ALIGN="CENTER">
<P>39</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Mel, Eto, Cy, Th</P>
</TD>
<TD ALIGN="CENTER">
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Koscielniak-1997" TYPE="STUDY">Koscielniak 1997</LINK>
</P>
</TD>
<TD>
<P>Retrospective</P>
</TD>
<TD ALIGN="CENTER">
<P>27</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Mel, Eto, Car, BCNU</P>
</TD>
<TD ALIGN="CENTER">
<P>yes &amp; no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Horowitz-1993" TYPE="STUDY">Horowitz 1993</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>16 ¥</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Vin, Adr, Cy</P>
</TD>
<TD ALIGN="CENTER">
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kinsella-1988" TYPE="STUDY">Kinsella 1988</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>16</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Vin, Adr, Cy</P>
</TD>
<TD ALIGN="CENTER">
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kazanowska-1997" TYPE="STUDY">Kazanowska 1997</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>12</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Car, Vin, Ifo, Eto</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pinkerton-1991_x002d_2" TYPE="STUDY">Pinkerton 1991-2</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>12</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Mel</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-Boulad-1998" TYPE="STUDY">Boulad 1998</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>10</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Mel, Eto</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Foot-1997" TYPE="STUDY">Foot 1997</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>8 ?</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Cy, Eto, Car</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Walterhouse-1999" TYPE="STUDY">Walterhouse 1999</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>8</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Th, Cy, Car</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lafay_x002d_Cousin-2000" TYPE="STUDY">Lafay-Cousin 2000</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>7</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Th</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hawkins-2002" TYPE="STUDY">Hawkins 2002</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>6</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Vin, Adr, Cy, Ifo, Eto</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Yamada-2007" TYPE="STUDY">Yamada 2007</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>6</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Mel, Eto, Car / Cy, Car, Eto</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bertuzzi-2002" TYPE="STUDY">Bertuzzi 2002</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>5 ?</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Mel, Mit or Th</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Blay-2000" TYPE="STUDY">Blay 2000</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Ifo, Eto, Cis</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Diaz-1999" TYPE="STUDY">Diaz 1999</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>5 ?</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Bu, Mel</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Williams-2004" TYPE="STUDY">Williams 2004</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>4</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Eto, Cy +/- Mel</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Melagolowkin-1999" TYPE="STUDY">Melagolowkin 1999</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>4</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Car, Eto, Mel</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ohira-1990" TYPE="STUDY">Ohira 1990</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>4 ?</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Cy or Mel</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kavan-1997" TYPE="STUDY">Kavan 1997</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Car, Eto, Mel</P>
</TD>
<TD ALIGN="CENTER">
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hara-1998" TYPE="STUDY">Hara 1998</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Th, Mel</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Endo-1996" TYPE="STUDY">Endo 1996</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Mel or Ifo, Car, Eto</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ekert-1984" TYPE="STUDY">Ekert 1984</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Vin, Cy, Dac, Mel, Act</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fraser-2006" TYPE="STUDY">Fraser 2006</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>2 ?</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Bu, Mel, Th</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kuhne-2000" TYPE="STUDY">Kuhne 2000</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Cy, Th, Mel, Eto</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Matsubara-2003" TYPE="STUDY">Matsubara 2003</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Mel or Mel, Eto, Car</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pession-1999" TYPE="STUDY">Pession 1999</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>2 ?</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Bu, Eto, Th</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Czyzewski-1999" TYPE="STUDY">Czyzewski 1999</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>2 ?</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Th, Car, Eto or Cy, Car or TBI + Mel, Eto or TBI + Cy,Th</P>
</TD>
<TD ALIGN="CENTER">
<P>yes &amp; no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Navid-2006" TYPE="STUDY">Navid 2006</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Cy, Eto</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Perentesis-1999" TYPE="STUDY">Perentesis 1999</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Eto, Th, Cy or Bu, Mel, Th</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Benchekroun-2008" TYPE="STUDY">Benchekroun 2008</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>1 ?</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Mel, Eto, Cy</P>
</TD>
<TD ALIGN="CENTER">
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bornbeck-2007" TYPE="STUDY">Bornbeck 2007</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Top, Eto, Car, Cy</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Donker-2009" TYPE="STUDY">Donker 2009</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Eto, Cy</P>
</TD>
<TD ALIGN="CENTER">
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ghavamdazeh-2009" TYPE="STUDY">Ghavamdazeh 2009</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>1 ?</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>?</P>
</TD>
<TD ALIGN="CENTER">
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kasper-2004" TYPE="STUDY">Kasper 2004</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Ifo, Car, Eto or Mel or Mel, Eto, or Mel, Bu</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Oue-2003" TYPE="STUDY">Oue 2003</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Ifo, Mel, Bu, Th</P>
</TD>
<TD ALIGN="CENTER">
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pico-1993" TYPE="STUDY">Pico 1993</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>1 ?</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Eto, Cy, Car</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mackall-2008" TYPE="STUDY">Mackall 2008</LINK>
</P>
</TD>
<TD>
<P>&lt; 20 patients</P>
</TD>
<TD ALIGN="CENTER">
<P>Unknown, awaiting full publication</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>Cy, Mel</P>
</TD>
<TD ALIGN="CENTER">
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Aleinikova-2002" TYPE="STUDY">Aleinikova 2002</LINK>
</P>
</TD>
<TD>
<P>Review</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>RE</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rosti-2002" TYPE="STUDY">Rosti 2002</LINK>
</P>
</TD>
<TD>
<P>Review</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>RE</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Atra-2002" TYPE="STUDY">Atra 2002</LINK>
</P>
</TD>
<TD>
<P>Review</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>RE</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ladenstein-1997" TYPE="STUDY">Ladenstein 1997</LINK>
</P>
</TD>
<TD>
<P>Review</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>RE</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gratwohl-2004" TYPE="STUDY">Gratwohl 2004</LINK>
</P>
</TD>
<TD>
<P>Review</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>RE</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Graham_x002d_Pole-1995" TYPE="STUDY">Graham-Pole 1995</LINK>
</P>
</TD>
<TD>
<P>Review</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>RE</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bader-1989" TYPE="STUDY">Bader 1989</LINK>
</P>
</TD>
<TD>
<P>No HDC</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>No high-dose chemotherapy given</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Stea-1987" TYPE="STUDY">Stea 1987</LINK>
</P>
</TD>
<TD>
<P>No HDC</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD ALIGN="CENTER">
<P>No high-dose chemotherapy given</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hartmann-1986" TYPE="STUDY">Hartmann 1986</LINK>
</P>
</TD>
<TD>
<P>No st. IV RMS</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rzepecki-2006" TYPE="STUDY">Rzepecki 2006</LINK>
</P>
</TD>
<TD>
<P>No st. IV RMS</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>CS</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<I>Footnotes</I>
</P>
<P>* CS = case series, HDC = high-dose chemotherapy, RE = review, RMS = rhabdomyosarcoma</P>
<P>&#8224; Cy = cyclofosfamide, Mel = melphalan, Th = thiotepa, Eto = etoposide, Cis = cisplatin, Car = carboplatin, Ifo = ifosfamide, Mit = mitoxantrone, Bu = busulfan, Vin = vincristine, Adr = adriamycin, Act = actinomycin-D, Dac = dacarbazine</P>
<P>¥ Not clear, probably same patients as Kinsella, no answer to repeated requests for information</P>
<P>? Exact number of naive stage IV RMS patients not clear in original article, stated number is maximal number of patients. Mainly not clear because presented number is a mixture of relapsed cases, patients with progressive disease and stage IV RMS patients</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-09-20 12:43:23 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-07-03 12:39:25 +0200" MODIFIED_BY="[Empty name]">Search strategy for PubMed</TITLE>
<APPENDIX_BODY MODIFIED="2010-09-20 12:43:23 +0200" MODIFIED_BY="[Empty name]">
<P>1. For<I>
<B> Rhabdomyosarcoma </B>
</I>the following MeSH headings and text words were used:</P>
<P>rhabdomyosarcom* OR rhabdomyosarcoma OR rhabdomyosarcomas OR embryonal rhabdomyosarcom* OR embryonal rhabdomyosarcoma OR embryonal rhabdomyosarcomas OR rhabdomyosarcomas, embryonal OR alveolar rhabdomyosarcom* OR alveolar rhabdomyosarcoma OR alveolar rhabdomyosarcomas OR rhabdomyosarcomas, alveolar OR myosarcom* OR myosarcoma OR myosarcomas OR soft tissue sarcom* OR soft tissue sarcoma OR soft tissue sarcomas.</P>
<P>2. For<I>
<B> Children and young adults </B>
</I>the following MeSH headings and text words were used:</P>
<P>infant OR infan* OR newborn OR newborn* OR new-born* OR baby OR baby* OR babies OR neonat* OR child OR child* OR schoolchild* OR schoolchild OR school child OR school child* OR kid OR kids OR toddler* OR adolescent OR adoles* OR teen* OR boy* OR girl* OR minors OR minors* OR underag* OR under ag* OR juvenil* OR youth* OR kindergar* OR puberty OR puber* OR pubescen* OR prepubescen* OR prepuberty* OR pediatrics OR pediatric* OR pediatric* OR peadiatric* OR schools OR nursery school* OR preschool* OR pre school* OR primary school* OR secondary school* OR elementary school* OR elementary school OR high school* OR highschool* OR school age OR schoolage OR school age* OR schoolage* OR infancy OR schools, nursery OR infant, newborn OR young adult OR young adults.</P>
<P>3. For<I> <B>Autologous or allogenic stem cell rescue </B>
</I>the following MeSH headings and text words were used:</P>
<P>bone marrow transplantation OR bone marrow grafting OR bone marrow cell transplantation OR stem cell transplantation OR stem cell transplantations OR hematopoietic stem cell transplantation OR peripheral blood stem cell transplantation OR peripheral stem cell transplantation OR cord blood stem cell transplantation OR placental blood stem cell transplantation OR umbilical cord stem cell transplantation OR mesenchymal stem cell transplantation OR autograft OR autografts OR transplantation, autologous OR autotransplant OR autotransplants OR ABMT OR PBSCT OR transplant* OR homolog* OR allogen*OR autolog* OR BMT OR myeloablative therapy OR myeloablative agonist OR myeloablative agonists OR myeloablativ* OR mega therapy OR stem cell rescue OR bone marrow rescue OR high-dose therapy OR high dose therapy OR allogeneic transplantation OR allogeneic transplantations OR homograft OR homografts OR homologous transplantation OR homologous transplantations OR transplantations, homologous OR transplantation, homologous OR transplantations, allogeneic OR transplantation, allogeneic OR allograft OR allografts.</P>
<P>4. For <I>
<B>RCTs and CCTs </B>
</I>the highly sensitive search strategy as described in the Cochrane Reviewers' Handbook was used (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>):</P>
<P>(randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR ("clinical trial" [tw]) OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR (placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:NoExp] OR comparative study [mh] OR evaluation studies [mh] OR follow-up studies [mh] OR prospective studies [mh] OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animals [mh] NOT humans [mh]))</P>
<P>5. For finding <B>case series</B> the following MeSH headings and text words were used:<BR/>patient series OR case series OR non-controlled clinical trial OR consecutive patients</P>
<P>Finally, searches were combined:</P>
<P>6. 1 AND 2 AND 3 AND (4 OR 5)</P>
<P>[* = 1 or more characters; pt = publication type; mh = MeSH heading; tw = text word]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2010-09-20 12:43:56 +0200" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-09-20 12:43:34 +0200" MODIFIED_BY="[Empty name]">Search strategy for EMBASE (Ovid)</TITLE>
<APPENDIX_BODY MODIFIED="2010-09-20 12:43:56 +0200" MODIFIED_BY="[Empty name]">
<P>1. For<I>
<B> Rhabdomyosarcoma </B>
</I>the following Emtree terms and text words were used:</P>
<P>1. Rhabdomyosarcoma/ or embryonal rhabdomyosarcoma/<BR/>2. Soft Tissue Sarcoma/ or myosarcoma/<BR/>3. (myosarcom$ or myosarcoma or myosarcomas or soft tissue sarcom$ or soft tissue sarcoma or soft tissue sarcomas).mp.<BR/>4. (rhabdomyosarcom$ or rhabdomyosarcoma or rhabdomyosarcomas).mp.<BR/>5. (embryonal rhabdomyosarcom$ or embryonal rhabdomyosarcoma or embryonal rhabdomyosarcomas or embryo rhabdomyosarcoma).mp.<BR/>6. (alveolar rhabdomyosarcom$ or alveolar rhabdomyosarcoma or alveolar rhabdomyosarcomas or alveolus-like rhabdomyosarcoma).mp.<BR/>7. (botryoid sarcoma or botryoid rhabdomyosarcoma).mp.<BR/>8. or/1-7</P>
<P>2. For <I>
<B>Children and young adults </B>
</I>the following Emtree terms and text words were used:</P>
<P>1. infant/ or infancy/ or newborn/ or baby/ or child/ or preschool child/ or school child/<BR/>2. adolescent/ or juvenile/ or boy/ or girl/ or puberty/ or prepuberty/ or pediatrics/<BR/>3. primary school/ or high school/ or kindergarten/ or nursery school/ or school/<BR/>4. or/1-3<BR/>5. (infant$ or (newborn$ or new born$) or (baby or baby$ or babies) or neonate$).mp.<BR/>6. (child$ or (school child$ or schoolchild$) or (school age$ or schoolage$) or (pre school$ or preschool$)).mp.<BR/>7. (kid or kids or toddler$ or adoles$ or teen$ or boy$ or girl$ or <I>young adult or young</I> <I>adults</I>).mp.<BR/>8. (minors$ or (under ag$ or underage$) or juvenil$ or youth$).mp.<BR/>9. (puber$ or pubescen$ or prepubescen$ or prepubert$).mp.<BR/>10. (pediatric$ or paediatric$ or peadiatric$).mp.<BR/>11. (school or schools or (high school$ or highschool$) or primary school$ or nursery school$ or elementary school or secondary school$ or kindergar$).mp.<BR/>12. or/5-11<BR/>13. 4 or 12</P>
<P>3. For<I>
<B> Autologous or allogenic stem cell rescue </B>
</I>the following Emtree terms and text words were used:</P>
<P>1. (stem cell rescue or bone marrow rescue).mp.<BR/>2. (bone marrow transplantation or bone marrow grafting).mp.<BR/>3. (bone marrow cell transplantation or stem cell transplantation or stem cell transplantations).mp.<BR/>4. (hematopoietic stem cell transplantation or peripheral blood stem cell transplantation).mp.<BR/>5. (peripheral stem cell transplantation or cord blood stem cell transplantation).mp.<BR/>6. (placental blood stem cell transplantation or umbilical cord stem cell transplantation).mp.<BR/>7. mesenchymal stem cell transplantation.mp.<BR/>8. (autograft or autografts).mp.<BR/>9. (autologous transplantation or autotransplant or autotransplants).mp.<BR/>10. (BMT or ABMT or PBSCT).mp.<BR/>11. transplant$.mp.<BR/>12. autolog$.mp.<BR/>13. (bone marrow transplant or bone marrow transfusion or bone marrow graft).mp.<BR/>14. myeloablative therapy.mp.<BR/>15. (myeloablative agonist or myeloablative agonists).mp.<BR/>16. myeloablativ$.mp.<BR/>17. mega therapy.mp.<BR/>18. (high-dose therapy or high dose therapy).mp.<BR/>19. (homograft or homografts).mp.<BR/>20. (homologous transplantation or homologous transplantations).mp.<BR/>21. (allogeneic transplantation or allogeneic transplantations).mp.<BR/>22. (allograft or allografts).mp.<BR/>23. (homolog$ or allogen$).mp.<BR/>24. or/1-23<BR/>25. Mesenchymal Stem Cell Transplantation/ or Autologous Bone Marrow Transplantation/<BR/>26. Allogenic Bone Marrow Transplantation/ or Bone Marrow Transplantation/<BR/>27. allogen$.mp.<BR/>28. bone marrow rescue/ or Myeloablative Agent/<BR/>29. Stem Cell Transplantation/<BR/>30. Allogenic Bone Marrow Transplantation/<BR/>31. Allogeneic stem cell transplantation/ or autologous stem cell transplantation/<BR/>32. Peripheral Blood Stem Cell Transplantation/<BR/>33. Cord Blood Stem Cell Transplantation/<BR/>34. Hematopoietic Stem Cell Transplantation/<BR/>35. autograft/ or allograft/<BR/>36. Autotransplantation/ or Allotransplantation/<BR/>37. or/25-36<BR/>38. 24 or 37</P>
<P>4. For<I>
<B> RCTs and CCTs </B>
</I>the following Emtree terms and text words were used:</P>
<P>1. Clinical Trial/<BR/>2. Controlled Study/<BR/>3. Randomized Controlled Trial/<BR/>4. Double Blind Procedure/<BR/>5. Single Blind Procedure/<BR/>6. Comparative Study/<BR/>7. RANDOMIZATION/<BR/>8. Prospective Study/<BR/>9. PLACEBO/<BR/>10. Phase 2 Clinical Trial/<BR/>11. phase 3 clinical study.mp.<BR/>12. phase 4 clinical study.mp.<BR/>13. Phase 3 Clinical Trial/<BR/>14. Phase 4 Clinical Trial/<BR/>15. or/1-14<BR/>16. allocat$.mp.<BR/>17. blind$.mp.<BR/>18. control$.mp.<BR/>19. placebo$.mp.<BR/>20. prospectiv$.mp.<BR/>21. random$.mp.<BR/>22. ((singl$ or doubl$ or trebl$ or tripl$) and (blind$ or mask$)).mp.<BR/>23. (versus or vs).mp.<BR/>24. (randomized controlled trial$ or randomised controlled trial$).mp.<BR/>25. controlled clinical trial$.mp.<BR/>26. clinical trial$.mp.<BR/>27. or/16-26<BR/>28. Human/<BR/>29. Nonhuman/<BR/>30. ANIMAL/<BR/>31. Animal Experiment/<BR/>32. or/29-31<BR/>33. 32 not 28<BR/>34. (15 or 27) not 33</P>
<P>5. For <B>Case series</B> the following Emtree terms and text words were used:</P>
<P>1. patient series.mp.<BR/>2. case series.mp.<BR/>3. non-controlled clinical trial.mp.<BR/>4. consecutive patients.mp.<BR/>5. or/1-4<BR/>6. 1 AND 2 AND 3 AND (4 OR 5)</P>
<P>[mp = title, abstract, subject headings, heading word, drug trade name, origional title, device manufacturer, drug manufacturer name; $ = 1 or more character; / = Emtree term]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2010-02-01 10:26:26 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2010-02-01 10:26:26 +0100" MODIFIED_BY="[Empty name]">Search strategy for Cochrane Central Register of Controlled Trials (CENTRAL)</TITLE>
<APPENDIX_BODY MODIFIED="2010-02-01 10:19:59 +0100" MODIFIED_BY="[Empty name]">
<P>1. For<I>
<B> Rhadomyosarcoma </B>
</I>the following text words were used:</P>
<P>(rhabdomyosarcom* OR rhabdomyosarcoma OR rhabdomyosarcomas OR embryonal rhabdomyosarcom* OR embryonal rhabdomyosarcoma OR embryonal rhabdomyosarcomas alveolar rhabdomyosarcom* OR alveolar rhabdomyosarcoma OR alveolar rhabdomyosarcomas OR myosarcom* OR myosarcoma OR myosarcomas OR soft tissue sarcom* OR soft tissue sarcoma OR soft tissue sarcomas)</P>
<P>2. For <I>
<B>children and young adults </B>
</I>the following text words were used:</P>
<P>(infant OR infan* OR newborn OR newborn* OR new-born* OR baby OR baby* OR babies OR neonat* OR child OR child* OR schoolchild* OR schoolchild OR school child OR school child* OR kid OR kids OR toddler* OR adolescent OR adoles* OR teen* OR boy* OR girl* OR minors OR minors* OR underag* OR under ag* OR juvenil* OR youth* OR kindergar* OR puberty OR puber* OR pubescen* OR prepubescen* OR prepuberty* OR pediatrics OR pediatric* OR paediatric* OR peadiatric* OR schools OR nursery school* OR preschool* OR pre school* OR primary school* OR secondary school* OR elementary school* OR elementary school OR high school* OR highschool* OR school age OR schoolage OR school age* OR schoolage* OR infancy OR young adult OR young adults)</P>
<P>3. For<I>
<B> Autologous or allogenic stem cell rescue </B>
</I>the following text words were used:</P>
<P>(bone marrow transplantation OR bone marrow grafting OR bone marrow cell transplantation OR stem cell transplantation OR stem cell transplantations OR hematopoietic stem cell transplantation OR peripheral blood stem cell transplantation OR peripheral stem cell transplantation OR cord blood stem cell transplantation OR placental blood stem cell transplantation OR umbilical cord stem cell transplantation OR mesenchymal stem cell transplantation OR autograft OR autografts OR autotransplant OR autotransplants OR ABMT OR PBSCT OR transplant* OR homolog* OR allogen* OR autolog* OR BMT OR myeloablative therapy OR myeloablative agonist OR myeloablative agonists OR myeloablativ* OR mega therapy OR stem cell rescue OR bone marrow rescue OR high-dose therapy OR high dose therapy OR Allogeneic Transplantation OR Allogeneic Transplantations OR Homograft OR Homografts OR Homologous Transplantation OR Homologous Transplantations OR Allograft OR Allografts)</P>
<P>Finally, searches were combined as (1) AND (2) AND (3)</P>
<P>The search was performed in title, abstract or keywords</P>
<P>[* = 1 or more characters]</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>